

OBN supporting and bringing together the UK's life sciences companies, corporate partners and investors

# CONNECT



## SPOTLIGHT: The Future of Talent in Life Sciences

An insight from Oxford Biomedica into the critical role that they play in growing and supporting the UK's emerging talent.

# BioTrinity 2021

Inspiring growth and creating opportunities in life sciences



## A FULLY HYBRID CONFERENCE EXPERIENCE

### SPONSOR SHOWCASE ATTEND

## JUNE 21-25 2021

Organised by



[www.BioTrinity.com](http://www.BioTrinity.com)

@BioTrinity

#BioTrinity2021

## CONTENTS

Celebrating the Success of the OBN Network .....	04
Oxfordshire's Got Some Incredible Talent .....	06
Future of Talent in the Life Sciences .....	10
The Diversification of CRO Services .....	14
The Rosalind Franklin Institute .....	18
The Future of R&D Tax Relief for the Life Sciences Sector .....	22
Powerful Testing Capability at Oncologica .....	26
Rolling Out Hope .....	30
How is Insurance Adapting to the Changing Landscape .....	32
An Introduction to Geroscience .....	36
Biotech Bull Dog .....	40
Directory of OBN Members .....	44



### Contact details:

#### Main Office

OBN (UK) Ltd  
5F Park Square, Milton Park, Abingdon,  
Oxfordshire, OX14 4RR, UK

**Tel:** +44 (0) 1235 420 870

#### Events Enquiry:

[events@obn.org.uk](mailto:events@obn.org.uk)

#### Membership Enquiry:

[membership@obn.org.uk](mailto:membership@obn.org.uk)

#### General Enquiry:

[info@obn.org.uk](mailto:info@obn.org.uk)



## Welcome to CONNECT

**My name is John Harris, the CEO of OBN Group and I'd like to personally welcome each of you to this fourth edition of CONNECT, OBN's bi-annual magazine.**

We are still living through challenging times as the COVID-19 pandemic continues to affect us all in a multitude of ways. Not surprisingly therefore, a significant proportion of this **CONNECT** is devoted to this topic, but from a positive stance; the enormous contribution that our Members and community have made to alleviate the worst aspects, provide genuine hope, and facilitate a roadmap back to normality.

Content includes the University of Oxford which drove the successful development of a 'vaccine for the world' in record time, the logistics behind the successful vaccine programme, and the development of home testing kits.

As spring proceeds and the vaccine rollout continues apace, there is the genuine expectation of better times ahead, and we are particularly excited to be delivering our OBN Awards event in London on 11th June, and BioTrinity on 21st June – 'Freedom Day!'

Of course, COVID-19 is not the be-all and end-all ... life still goes on, so this edition also includes a range of other topics such as geroscience, talent, taxation / fiscal issues, an introduction to the Rosalind Franklin Institute, and thought-provoking opinion.

We hope you find this **CONNECT** an informative and interesting read and very much welcome your feedback.

Follow us on:  @OBN\_UK  OBN (UK) Ltd

Visit us online: [www.obn.org.uk](http://www.obn.org.uk)

CONNECT is OBN'S Membership Magazine produced twice a year. It is designed and printed by Incorporate Design. The main purpose of CONNECT is to provide updates on current sector issues and a listing of OBN Members and supporters. Our readers are from companies and organisations who operate within the life sciences industry in sectors such as Therapeutic Discovery and Development, Medtech, CXO/Consultancy, Academia, R&D Support and Supply, Investment, Charity and Government. The Members Directory was up-to-date at the time when this magazine was collated and will always be subject to change. Any opinions expressed by those quoted in this magazine are their own and do not necessarily represent or reflect those of OBN (UK) Ltd. No part of this publication may be reproduced or used in any form of advertising or promotion without permission of OBN (UK) Ltd.

# OBN NETWORK NEWS

Spring is definitely on the way, the COVID-19 vaccination programme is proceeding at pace and it feels as though normality will be resumed any time soon. It's been challenging but we have survived not least due to the continuous engagement with our Sponsors, Supporters and Members during these 'interesting times' – thank you! Looking forward, the 2021 calendar is maturing nicely and we anticipate seeing Members at face-to-face at events shortly.

It is fair to say that the [OBN events calendar](#) has never been so busy. Fully embracing the possibilities of digital/virtual access has provided the opportunity to bring people together as never before. Certainly, we have been in contact with people we would never have met due to the ease of setting up 'Zoom' meetings and events. Looking at the registrations for our events we are seeing an increasing number of registrants from outside the UK. Certainly, it will be most welcome to return to F2F meetings however keeping the virtual aspect going is something we aim to do.

*BioTrinity, our major meeting of the year (21-25th June in LONDON), will be the first 'normal' event of the year for the sector*

Talking of F2F events, BioTrinity, our major meeting of the year (21-25th June in LONDON), will be the first 'normal' event of the year for the sector. Delegates will be attending in person or virtually and the setup will allow full participation regardless. Keep an eye on the BioTrinity site as we develop the programme – a few changes for this year include the Industry Insight sessions aimed at putting the science at the forefront with keynotes/presentations from leading players. This is complemented with BioLaunchPad for companies to pitch or update the audience. We are also working hard on assembling a poster session for academics to showcase some of the best happening in UK academia.

Just prior to BioTrinity we will be hosting the much-delayed 2020 OBN Awards. The event will be hosted at the Royal Lancaster Hotel in London on June 11th and will be a great way to celebrate achievement in the sector and the resilience through 2020. Please join us to enjoy and evening with friends and colleagues.

Looking at the early-stage company scene we were surprised and delighted at the attendance of companies and investors at BioSeed. We have followed up on many of the presenting companies and can report that many have secured investment, which we take as an indicator that the investment environment is returning to something approaching normal. The success of BioSeed and the fact that we could not host all the companies that wished to present prompted us to start BioSeed Lunchtime Express events. These will be quarterly events in a live digital format offering 7-minute presentations, Q&A, and appropriate for companies seeking up to £2.5M. No mention of investment should be made without mentioning a few Member companies that have been successful.

- **Vaccitech (\$168M Series B)**
- **CytoSeek (£3.5M)**
- **ExScientia (£79M)**
- **Fixed Phage (£4M)**
- **Antiverse (£1.4M)**
- **Carocell Bio**

To mention a few. **Great work!**

Looking further forward we are pleased to point to BioForward on September 23rd in Oxford. BioForward is our 'Roadmap for Growth' event and provides a platform for early-stage companies and service providers to get together – the aim being to facilitate transfer of 'know-how' and to develop connections that will speed company development. This will be the third run at the event, and we believe that we now have a good formula, so please come along.

**So, in summary 2021 is going to be a good year. We hope to see you at our events!**

To keep track of OBN's activities why not sign up for our mailers [here?](mailto:team@obn.org) [team@obn.org](mailto:team@obn.org)



We have welcomed many new members to the OBN Membership since the last edition of CONNECT - please see details below.

## Sponsors

Focus	A leading independent insurance broker providing specialist advice to both business and private clients and has been active in the sector for over 30 years.
-------	--

## Supporter

GenScript	A leading biotech company providing life sciences services and products.
-----------	--

## Full Members

ConserV Bioscience	A late-stage vaccine development company focused on advancing safe and effective vaccines that protect against endemic and emergent infectious diseases
Samsara Therapeutics	Developing therapeutics for diseases of aging, neurodegeneration and rare genetic disease
Evgen Pharma Plc	Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation
Ferryx	Live biotherapeutic products for the treatment of gut inflammation
coding.bio	Accelerating development of cell therapies through better approaches to biomolecule selection
Argonaute RNA	Developing safe and reliable methods or temporarily silencing target genes in different tissue or cells
LUNAC Therapeutics	Developing advanced life-saving anticoagulants with minimal risk of bleeding
Bayer AG	Bayer is a long-established global pharmaceutical company with diverse interests including pharmaceuticals, consumer health and crop sciences
Presymptom Health Limited	Developing life-saving diagnostic technology to detect sepsis earlier than current technologies and which will be able to significantly improve outcomes
AccendoLab Limited	A diagnostics company operating an approved Covid-19 testing laboratory
Fixed Phage Ltd	To design, development and commercialise applications which use stabilised phage to solve bacterial challenges.
Northern Balance	One of the UK's leading independent distributors of weighing equipment, supplying, servicing and calibrating some of the worlds most trusted brands

## Network Members

Stark Labs	STARKLABS was the first team to develop an alternate method for the depletion of senescent cells in age-related pathologies using immunotherapy.
Molecule 2 Medicine	Professional consulting services for small biotech companies to help them develop robust drug discovery and development programmes
Rosalind Franklin Institute	A new Research institute dedicated to transforming life science through interdisciplinary research and technology development
anvajo GmbH	A technology company that develops, manufactures and sells innovative solutions for the analysis of liquid samples
Helixr	Helixr is a business consulting firm offering services to life sciences companies across business restructuring, global tax technologies and ERP programs, including end-to-end project management solutions
Elementa Consulting	MEP building services and sustainability consultancy specialising in low energy building design
Jackson Hogg	Recruitment and outsourced staffing, HR consultancy, training provider
Restore Harrow Green	Laboratory relocation/storage and distribution

# OXFORDSHIRE'S GOT SOME INCREDIBLE TALENT



***Philip Campbell, MEPC commercial director, Milton Park, provides an insight into how Science Parks, such as Milton Park have been supporting the life sciences industry in nurturing such talent.***

*It's hard to find the words to describe the achievements of The University of Oxford and its partners which has given the world a masterclass in how to make a vaccine in record time.*

This incredible research and development project has been the result of talent: talent in the right place, with the right investment, with the right knowledge, facilities and connections.

In the 15 years I have been working at Milton Park, the drivers by businesses looking for lab space have been links to Oxfordshire's flourishing life sciences' ecosystem, flexibility to up or downsize its space, and access to talent.

For business owners, we've found that it's about how they can attract and keep their staff in an environment that allows them to thrive, not just in their buildings but around them with facilities, environment and opportunity. For them, the opportunity is about collaborating with their neighbours, sharing knowledge and experience and interacting...and having fun!

We have been supporting the life sciences industry and numerous Oxford University spin outs for more than 35 years. Evotec has had a presence at Milton Park ever since the company's merger with Oxford Asymmetry International plc in 2000. Oxford Asymmetry International had been based at Milton Park since 1989 and started in one of our original ex-MOD depot buildings.

At a recent OBN event 'Supporting the Life Sciences Ecosystem in Oxfordshire' Christophe Muller from Evotec said that they had welcomed 170 new people in the last 12 months at Park, with 654 employees on site and 38 nationalities with the average age of 36 and length of time at the company being 5.6 years. In that same period, Evotec has twice taken more office and lab space, making it one of the Park's largest occupiers alongside Immunocore and Adaptimmune, all of which started life at Milton Park as Oxford spinouts.

At that same event, Evotec, Ipsen, Pathios Therapeutics, Replimune and Grey Wolf Therapeutics said that the reason they had located and stayed at Milton Park was due to the access to great talent in Oxfordshire, the collaboration on site between companies, the high-quality facilities and excellent transport links, all of which make us

an attractive place for potential employees and therefore easier recruitment.

Companies such as Ipsen Bioinnovation has been growing at Milton Park since they arrived in 2015 and in 2019, they opened their new R&D centre employing more than 80 local people including 40 research scientists.

In addition, Module 2 Medicine which works with both Pathios Therapeutics and Grey Wolf Therapeutics, joined Milton Park in 2019 taking 309 sq ft in our innovation centre and in 2020, having seen fast growth, now occupies 2,676 sq ft making them the biggest occupier in our centre.

But as these businesses have grown and we see the next Immunocores of this world come through the Oxford spinout system, the question is, how much does location and place impact recruitment?

We recently developed our 2040 Vision, a big piece of work which looked at our emerging masterplan and how we sustainably grow from 9,000 people to 20,000 people to support the demand for businesses needed not just office and laboratory space but a connected and thriving place.

In this we carried out some baseline analysis evaluating several economic and demographic factors that have influence on the future success of business at the Park.

*For business owners, we've found that it's about how they can attract and keep their staff in an environment that allows them to thrive, not just in their buildings but around them with facilities, environment and opportunity.*



The most pressing issue identified was the national shortage of housing provision. The area around us identified proximity to some of the more affordable housing in the region compared to the UK average of £232,554 and Oxford average of £483,400 (Gov.UK, HPI April 2018).

Future housing developments, including the 15,050 within the Didcot Garden Town bid, are supporting the affordable housing provision and mix of housing types available to people working at Milton Park. Anecdotally, one of our most popular pages on our website is our jobs board which is for our customers to advertise vacancies for free. People want to be based at Milton Park, and if they're looking for a job change, they want to stay in the same place rather than commute further afield.

We are investing in street connectivity to provide walking and cycling connections through the Park and onto Abingdon, Oxford and the surrounding villages and towns. We have also recently partnered with Thames Travel on new bus services which extend our very popular £20 annual pass which now provides free travel for Milton Park employees to the whole of Didcot Zone 1. The future is about people getting to work easily, safely and sustainability.

We asked people what their favourite elements of the Park were. The number one thing was the green spaces, followed by amenities, walking, landscape and location. The green and natural aspects of the Park outweighed all the other comments. I believe that these elements are more vital than ever to support people's health and wellbeing as people start to return to work as schools reopen and government lockdown restrictions ease.

For Milton Park to continue to retain its occupiers

while also attracting new science and tech companies, we need to build on our green credentials, continue to evolve to meet our customers' needs and focus on being an inclusive community.

Being a single ownership estate, when our customers come to us needing to downsize or upsize, we are able to be flexible and adaptive. The recent pandemic has seen both these situations happen but by being on our customers' sides through the hard times, they know that we are here for them in the long term.

We have been able to pivot quickly with initiatives such as extending the bus timetable to support the keyworkers who work in labs and have been using the late service and introducing touch-free pedestrian crossings. By giving people a supportive, certain and fun environment, they can continue their focus on their business and retaining and attracting their talent.

We continue to invest in creative and innovation space. We have exciting plans which we will unveil this year which will cater to the fact that people don't want to be travelling into the London on the train five days a week. We are seeing demand for flexible and hybrid innovation space from those people who live in Oxfordshire but have commuted into cities for work and have had a taste of the bonus extra time they have had by not commuting. We are pivoting fast to accommodate this new demand.

We forecast that such seismic workplace shifts will bring new forms of talent back into the county, new opportunities to expand the commercial ecosystem and new situations for collaboration and investment.

As we pull out from this long, tough winter, it really is about 'building back better'. It's about investing in places and people so that companies can thrive, so that the economy can reboot, and we can continue to be a facilitator of life changing discoveries.

But also, we need to remember that we are social creatives and need interaction, so we have plans to help put the fun back into work through events, networking and collaboration.

**And finding a word to epitomise the Oxford Covid vaccine team? We'll find one and we will celebrate their incredible talent. ■**



## ///scores.honey.ambitions

You may have heard of ///what3words.

It's the simplest way to talk about location.

We discovered that our three-metre square at the front door of our Oxfordshire Innovation Centre epitomises our place and the pioneering and life-changing work that happens on the 135,800 other three-metre squares on the park and our sustainability initiatives.

Find out more about how this discovery encapsulates our science and technology community and our 2040 vision:  
[miltonpark.co.uk/what3words](https://miltonpark.co.uk/what3words)

Join us.

Where life and work connect

AN **MEPC** ASSET

.....  
*We are seeing demand for flexible and hybrid innovation space from those people who live in Oxfordshire but have commuted into cities for work and have had a taste of the bonus extra time they have had by not commuting. We are pivoting fast to accommodate this new demand.*  
.....



# THE FUTURE OF TALENT IN THE LIFE SCIENCES INDUSTRY



An insight from Oxford Biomedica into the critical role that they play in growing and supporting the UK's emerging talent and reflecting on the recent BioTuesday about why it is important to look at what 'talent' actually means.

The future talent needs of the life sciences industry, specifically within gene and cell therapy are growing. The industry is moving at great pace, with high demand for niche skills. The good news is that the UK has had a record high in the number of students choosing to study STEM subjects at university in the past few years.

However, we currently do not know what the longer-term effects of the COVID-19 pandemic could be. Students studying at all levels have been impacted by remote learning. Will their choices for further education be affected? Will a skills gap be created that will need to be accounted for within schools and universities in the coming years? We simply don't know enough at this stage to answer these questions.

Furthermore, the UK has benefited from the freedom of working across the EU for many years, attracting the scarce talent required to meet business needs. However, with Brexit, companies will incur the cost and time associated with obtaining visas for the much sought-after talent that is not available in the UK.

If we look closer at early talent, experts predict that by 2025, 75 percent of the workforce will

be millennials. For millennials, workplace culture and technology are important factors when choosing their future employers. Of particular interest are company values and purpose, diversity, and responsible business cultures, with the need to feel an emotional connection.

Offering apprenticeships has enabled Oxford Biomedica to hire and train some of the talent it needs for the future. Apprenticeships play a key role in helping us to continue growing our diverse and inclusive workforce. By offering students the opportunity to learn on the job whilst obtaining a qualification, students from lower social-economic backgrounds can achieve their goals without the burden of student debt. Teaching our apprentices, the skills and knowledge they need to succeed allows us to grow our own talent, which is a significant benefit to our business.



Offering apprenticeships has enabled Oxford Biomedica to hire and train some of the talent it needs for the future. Apprenticeships play a key role in helping us to continue growing our diverse and inclusive workforce.

.....  
*"I don't think that it reflects what it takes to succeed and make a contribution to science, but I do think they reflect some of the perceptions and structures and incentives that are maybe contributing to a lack of diversity in progressions and retention, so I think the two are linked."*  
.....

In collaboration with our university providers, we have written content for course modules, which helps to ensure apprentices are ready for the workplace. We currently have eighteen apprentices at various levels and will be hiring a further ten this year. In addition, to help bolster our early careers offering, we also employ two PhD students and have four industrial placements students joining us in September.

As we continue our early careers journey, we accept that we have a responsibility to schools and universities to help educate and excite students, in the hope that we can encourage them to take scientific subjects at A-level. Our early careers strategy recognises that as a business, we have a critical role to play in growing and supporting the UK's emerging talent. We will be actively supporting lectures and providing careers guidance to local schools and a number of universities. We know that we can make a positive impact. Showing students what future career opportunities are available, to them in the cell and gene therapy industry, is just the beginning of our exciting early careers journey.

In February 2021 we held our monthly BioTuesday focused on 'The Future of Talent in the Life Sciences Industry', and our panel of thought leaders addressed what the word 'talent' meant to them and considered how we can optimise the flow of talent into the industry, by engaging with a broader range of candidates through non-traditional channels. It was interesting to hear from

Anna Zecharia, Director of Policy & Public Affairs at British Pharmacological Society who provided her thought-provoking ideas on what the word 'talent' means and why it matters to challenge what it means.

Anna considers that the word reinforces the idea of being 'special' and 'elite' and more often focuses on the contribution of the individual. Many words used such as the 'brightest and the best' can be problematic.

"I don't think that it reflects what it takes to succeed and make a contribution to science, but I do think they reflect some of the perceptions and structures and incentives that are maybe contributing to a lack of diversity in progressions and retention, so I think the two are linked."

Anna feels strongly that we need to value everybody who contributes to science, and to invest in their training and development. We are heavily influenced by the society we live in which can put up barriers, and our duty is to remove the barriers and change the perception so that we are not forcing people into science.

Anna has looked at the dominating stereotypes associated with the word talent such as cleverness, the 'brightest and the best' and masculinity as they intercept people believing that science could be for them. The earlier we take these barriers down the better.

Making science available to everyone means that we need to be mindful of the language that we use. It is not about whether people like science necessarily but whether they see themselves able to achieve a career in it and having the route and opportunities that can bring this to life for them.

The global COVID-19 pandemic has been a unique opportunity to build engagement within research and clinicians, and the connection with clinical trials has really brought science to the forefront of many people's minds.

What is encouraging is that there is change happening and important opportunities coming especially with the recognition that the government is giving to science.

A career in life sciences can be life changing, and everyone should have the opportunity, support, and access to explore a career in life sciences. ■



Celebrating Innovation & Achievement in Life Sciences



**OBN AWARDS 2020**  
LONDON 11 JUNE 2021

Nine Kings Suite,  
Royal Lancaster Hotel  
London W2

[www.obn-awards.com](http://www.obn-awards.com)  
@OBN\_UK  
#OBNAwards

# THE DIVERSIFICATION OF CRO SERVICES:

a shift from solutions to capabilities



*Precision for Medicine reveal the merging of bespoke consultancy services with clinical trial CROs*

*For many years CRO's focused on "full service" offerings to meet the varied trial needs of our clients. These "one-stop-shop" solutions were seen as the simplest path towards achieving client goals. Not only did this approach eliminate the client's need to manage how individual parts work together, it allowed sponsors to partner with CROs and share risk across an entire portfolio.*

Fast forward to today's environment in which sponsors increasingly want to cherry pick services from multiple suppliers to get the best of not one, not two, but several entities. They get some safety work here, monitoring there, regulatory services elsewhere – and data science from yet another group. Biostatistics, data management, and medical writing are all selectively outsourced. These strategic partnerships for individual service lines build a new type of brand loyalty based on previous working relationships.

And why not? Unless a sponsor uses the same CRO for every study, they are already managing multiple vendor relationships; this new approach may help them link specific skill sets across studies, building capability-based strategic partnerships that create deeper consistency.

An additional driver of change may be the rise in small and medium enterprises with limited in-house resources – organizations that don't have internal data science, safety, and regulatory arms, and so seek strategic partners to provide these services. Even mid- and large-pharmaceutical companies may prefer to outsource some of these functions, creating a more agile workforce, especially given the rapid pace of technological change.

The result: a merging of bespoke consultancy services with clinical trial CROs.

*They get some safety work here, monitoring there, regulatory services elsewhere – and data science from yet another group.*






This new approach is shaping our industry to become significantly more client-centric, encouraging our traditional supporting roles to seriously consider how they measure up against the competition. These are not apples to apples comparisons; every CRO has a unique approach to efficiencies both in system and process.

This healthy competition engenders creativity, as we question long-standing historic approaches. We need to continuously improve

– and we need to clearly differentiate our offerings in this crowded environment, even when we are internally aligned. We ask: Can we achieve the same result in half the time with the same level of quality? Do we have the experience to ride out stumbles along the way? Do our bespoke systems provide more real-time transparency into what's important? These are all valid ways of helping differentiate areas of our industry not normally under a spotlight.

The competitive nature of the CRO world ensures that any unique offering doesn't remain unique for long. Continuous improvement comes into play – and so the cycle continues. Our clients – and more importantly the patients we serve – benefit from this plethora of choice and a marketplace which remains open to selectively choosing the best solution to every problem. ■

.....  
*Our clients – and more importantly the patients we serve – benefit from this plethora of choice and a marketplace which remains open to selectively choosing the best solution to every problem.*  
.....



## Trials + Labs + Data combined to accelerate clinical development


Precision medicine has unique requirements—and our clinical research services organization is custom-built to meet them. We integrate clinical trial execution with deep scientific knowledge, laboratory expertise, and advanced data sciences. Together, these strengths help life science innovators speed life-changing therapies to patients.

The CRO for Precision Medicine  
[precisionformedicine.com](http://precisionformedicine.com)

PRECISION  
for medicine

# THE ROSALIND FRANKLIN INSTITUTE:

## A new home for skills and talent in Oxfordshire



*Interview with scientists about what is it like working at the Rosalind Franklin Institute and why they enjoy it....*

The Franklin is a newcomer in the research landscape, as a new institute with a state-of-the-art hub on the Harwell campus, backed by a £100m investment from our funders at UK Research and Innovation's Engineering and Physical Sciences Research Council (EPSRC).

The Franklin is tasked with developing technologies which will change the way we see life – using advanced imaging with electrons to reveal the atomic structures of cells, creating new imaging platforms in mass spectrometry, and developing techniques for true in-cell

chemistry, combined with high throughput drug discovery and access to protein tools, including nanobodies. All of our tools are underpinned by AI and analytics, enabling researchers to interpret the huge data sets produced.

### RESEARCHER SPOTLIGHT:



**Dr Anna Simmonds,**  
Postdoctoral  
Research Associate



**Dr Liang Wu,**  
Wellcome and Royal  
Society supported  
Henry Dale Fellow

**Here we introduce two great examples of young talent at The Franklin, Dr Liang Wu, a Wellcome and Royal Society supported Henry Dale Fellow based at The Franklin, and Dr Anna Simmonds, Postdoctoral Research Associate in Ion Mobility and Mass Spectrometric Instrumentation.**

**Q** What are you currently working on at The Franklin?

**Anna:** I am working on ion mobility instrumentation in our mass spectrometry theme, working with the instrumentation company Bruker to develop next generation devices.

**Liang:** I hold a Henry Dale Fellowship based at The Franklin, looking at the molecular basis of heparan sulfate formation. Heparan sulfate is a polysaccharide (sugar) in the body, which is vital for all sorts of processes from tissue development to kidney function. Very little is known about how it is made. Understanding this will have huge implications for biomedical sciences (tackling diseases where it goes wrong), and for biotechnology (making new heparan sulfate based biomaterials).

**Q** What keeps you excited about your research career?

**Anna:** I love working on ambitious projects – working on things that have never been done before. Of course, this

ferments a lot of failure, but it's worth it when the pieces come together.

**Liang:** Probably a childlike sense of wonder. I'm genuinely curious about how simple chemical processes can create something as complex as a living cell, let alone a whole organism. I also love trying out new techniques and technologies. Even though my project is not directly methods development, I still have a 'kid in sweet shop' feeling about working at the Franklin and being able to experience the cool new technologies being developed here.

**Q** What do you think are the most important skills a young researcher can gain early in their career to help them be successful in the research world today?

**Anna:** Coding. Definitely coding skills – gain as many as you can as early as possible. It saves so much time to be able to create your own 'short cuts', and to be able to understand the structure of the software tools we are using. Beyond that – being enthusiastic about the work you do and keeping that enthusiasm for research.

**Liang:** I think it's vital to develop a sense of what to do in a new research project. Much of our formative training is focussed on learning how to do the techniques we use in our work, but it's arguably more valuable to be able to look at a new problem and think up viable strategies to tackle it. You can always ask for help with techniques later!

**Q** We talk a lot about porosity in research careers – moving from academia to industry and back again. Do you see this as an increasing trend? What can we do to keep young talent in research?

**Anna:** I hope it is an increasing trend. Some of the coolest jobs are in industry where researchers can explore some really interesting ideas in a very independent way. I think this is probably also the

key to keeping researchers in the system – freeing researchers from traditional structures and giving them more options – at places like The Franklin – where they can spend time and develop before moving back into Universities, or on into Industry.

**Liang:** I agree with Anna. There certainly isn't much love lost for some parts of the traditional University academic system, especially by early career researchers. I think there is increasing recognition that academia isn't necessarily the best place to pursue exciting new blue-skies ideas anymore. More porosity can only be a good thing in my mind, enabling talented researchers to stay in the research ecosystem as a whole, rather than simply being tied to an academic or industry track. ■

.....  
*Much of our formative training is focussed on learning how to do the techniques we use in our work, but it's arguably more valuable to be able to look at a new problem and think up viable strategies to tackle it. You can always ask for help with techniques later!*  
 .....



# OBN Membership

JOIN OVER 400 MEMBER COMPANIES BENEFITING FROM OUR SERVICES

**Membership to OBN gives you access to partnering, purchasing, training, advice and advocacy. Learn from your peers and grow your business.**

#### Membership criteria

##### OBN Membership is open to:

- UK and international companies
- Investors
- Academic and research institutions
- Independent consultants
- Contract research organisations
- Public bodies
- Government departments
- Associated service providers in the life sciences sector

#### Membership Benefits Networking - Attend OBN events

- Connect with life sciences companies, their corporate partners and investors
- Expand your company's presentation opportunities
- BioTuesdays – evening meetings with a sector-relevant theme or a Company Showcase format
- BioThirstdays – evening social events to meet informally
- Senior Executive Club – Breakfast, Lunches and Dinners: invitation events, high level focus materials

**Plus many more..**

#### Advocacy

- Promoting Members' interests at local, regional and international level
- Attend exclusive events to connect with influencers and key decision makers

#### Partnering

- Up to £300 discounted registration at BioTrinity – OBN's flagship event and Europe's leading Biopartnering and Investment Conference. Engage with 1,000+ delegates from 30 countries
- Access conference discounts worth over £1,000 per person
- Request introductions to key personnel

#### Purchasing

- Access average savings of 50% off list price through the OBN Purchasing Consortium
- Buy alongside 140+ eligible Member companies
- Process managed by an in-house Procurement Manager
- Access to a new online Purchasing Platform

#### Training

- Use BioLearn® to access high level training tailored to the needs and requirements of life sciences staff at discounted prices

#### Advice

- Find facilities, equipment, expertise within the OBN Membership and in other geographical areas
- Make contacts through our partner organisations
- Canvass opinion and consult on key issues for your company
- Commission OBN Intelligence to address key issues for your organisation



To find out more about OBN Membership benefits visit: [obn.org.uk](http://obn.org.uk) or contact Nicola Westgate, Membership Manager, [nicola.westgate@obn.org.uk](mailto:nicola.westgate@obn.org.uk) or call +44 (0)7795 233883

# THE FUTURE OF R&D TAX RELIEF FOR THE LIFE SCIENCES SECTOR

*Katy Rabindran and Charlotte Crosby from BDO's R&D Life Sciences team consider the latest HM Treasury announcement*

*On Budget day 2021, the Government launched a wide-reaching review into the future of Research and Development Tax incentives in the UK - companies making R&D claims should consider what any changes could this mean for their business.*

## **The review will include:**

- The cash back rates for R&D incentives (currently small businesses can claim up to a third of R&D costs back in cash from HMRC).
- Whether the UK's two separate R&D tax schemes should be combined.
- The definition of R&D for tax relief purposes. Companies in the Life Sciences sector invest more in R&D than any other sector and are one of the biggest claimants of R&D relief - making up 20% of all claims made in the tax year to 2019. More recently, in the fight against COVID-19, the Life Sciences sector saw overall growth due to the increased demand for drug development and advancements in medical technology - all supported by R&D tax relief (alongside specific incentives).

The Government has set itself a target of raising total UK investment in R&D to 2.4% of GDP by 2027. As R&D tax relief is seen as one of the biggest drivers of R&D investment in the UK, it is important to ensure that the relief remains up to date, competitive and well-targeted. HMRC's comprehensive consultation seeks views from stakeholders on a number of fundamental aspects of the R&D schemes and where there may be improved.

## **Staying internationally competitive**

Several other countries around the world offer similar R&D tax incentives, all with varying levels of benefit and costs that can be claimed (see BDO's comparison of European regimes). However, the UK is unusual in that it has a separate SME (Small or medium enterprise) scheme and R&D expenditure credit (RDEC) for "large" companies. These use tests of group size and nature of work undertaken to determine eligibility. Broadly, the SME regime allows additional tax deductions of 130% of qualifying costs and enables tax credits for loss making businesses thereby triggering tax credits up to 33% of R&D spend while

the RDEC scheme is an "above the line" tax credit of 13% of qualifying costs. Most other countries tend to take a one size fits all approach, often offering a larger credit than the UK RDEC.

The consultation asks whether the SME and RDECs schemes should be merged, which could result in a standard relief percentage for all companies irrespective of size. Clearly, the aim is to reduce the complexities associated with having two schemes and it would benefit large companies if the new standard rate of relief was increased to stay internationally competitive. However, the question remains whether using one single overall rate would mean smaller businesses and start-ups lose out.



### Redefining R&D

Another key area covered by the consultation is to whether the current definition of R&D (which has seen few changes since the scheme was introduced in 2000) is still fit for purpose?

For a company involved in drug discovery, it is commonly accepted by HMRC that phases I to III of clinical trials would have qualifying activities for R&D, however any activities in phase IV would not typically qualify for the scheme. One key question for this sector is whether the definition should be expanded to allow for inclusion of these costs? Additionally, some companies which support the life sciences sector sometimes find they are ineligible (for

example routine testing work subcontracted out by large pharma). Here is an opportunity for the Government to further invest in the life sciences sector and encourage innovation in the UK by expanding this interpretation/ definition. Further, should the R&D definition be targeted to specific sectors such as life sciences and/ or to support wider Government goals such as reducing carbon emissions?

The past year has amplified the need for advances in medical technology and drug development. Focusing funding in these areas rather than other areas of R&D could be one of a number of suggestions to be made in the HMRC consultation. ■

*“Here is an opportunity for the Government to further invest in the life sciences sector and encourage innovation in the UK by expanding this interpretation/ definition.”*

Read the full consultation document 



### HAVE YOUR SAY

If advances in the field of life sciences are to continue, Government support is of key importance with R&D tax relief being one key relief used today. Therefore, it is critical for those within life sciences to have their say on both the key issues highlighted here and the wider review.

What changes you would like to see to the UK R&D rules?  
Take part in our quick survey.

## Partner4Pharma®

Partner4Pharma® events are tailored to meet the demands of mid-to-large size pharmaceutical organisations, who are seeking early stage assets in the UK life sciences sector.

The Partner4Pharma® platform allows access to OBN's network and sector knowledge to reach companies, organisations and academics in your target areas. The expertly delivered event will be organised to your specifications, bringing together your company's key personnel and your target organisations.

The OBN Partner4Pharma® service is developed to meet your core objectives and includes:

- The design of a bespoke search process that reaches new potential assets as identified in the project brief
- Driving the search process utilising the support of our in-house resources and experienced analyst
- Delivering results via the delivery of a digital or in-person event solution



Get in touch to find out how we can tailor an event for you

[events@obn.org.uk](mailto:events@obn.org.uk)

# POWERFUL TESTING CAPABILITY AT ONCOLOGICA



*Oncologica is now providing Coronavirus home testing kits to the wider community to facilitate a safe return to work - Astrid Ferlinz, Market Development Leader Genetic Testing Solutions EMEA at Thermo Fisher Scientific tells us the role that they are playing in providing Coronavirus home testing kits.*

The rapid implementation of the coronavirus vaccine in the UK is now having traction with rapidly falling death rates and a fall in the prevalence of COVID-19 infections. There is now light at the end of the tunnel with the staged relaxing of COVID restrictions over the next few months enabling a return to work and the opening of social settings.

SARS-CoV-2 PCR testing and sequencing will now play a critical role in preventing the spread of new mutant variants in the UK that have potential to bypass the vaccines. These technologies give critical insights into our understanding how the SARS-CoV-2 virus mutates, which variants are the most infectious and how it travels from place to place. Yet sequencing is still rare in most countries, and more than a year since the virus made its deadly debut much about it remains a mystery.


A new UK government regulation will accelerate the pace of genomic research into the virus and cement the U.K.'s leadership position in the field. As of February 15, all international travellers to Great Britain from so-called "red list" countries are required to quarantine for ten days and undergo a polymerase chain reaction (PCR) test, the gold standard for coronavirus detection, on days

two and eight. If the traveller tests positive, the sample must be sent to a government-approved lab for genomic sequencing. The rule was prompted by fears about the introduction of coronavirus variants that might prove resistant to vaccines. (The infamous B.1.1.7 variant, which was first identified in the U.K., does not appear to be vaccine resistant.)

Oncologica, a government-approved provider of COVID-19 testing and genomic sequencing, based in Cambridge is playing a leading role in the fight against variants in the UK using its fast Covid-19 testing and sequencing capabilities to screen travellers as part of the newly introduced day 2 and day 8 COVID-19 international travel testing programme. Oncologica is now providing Coronavirus home testing kits to the wider community including businesses, offices, factories, educational institutions and transport networks to facilitate a safe return to work.



*As of February 15, all international travellers to Great Britain from so-called "red list" countries are required to quarantine for ten days and undergo a polymerase chain reaction (PCR) test, the gold standard for coronavirus detection, on days two and eight.*



Prof Gareth Williams, MBChB, PhD, co-founder of Oncologica: "Our high throughput SARS-CoV-2 Corona focus testing and sequencing platform has been built exclusively around Thermo Fisher Scientific™ technologies. The **TaqPath™ COVID-19 CE-IVD RT-PCR** kit is a multiplex assay that targets three different SARS-CoV-2 genes (orf1ab, N gene, S gene), to compensate for emerging SARS-CoV-2 variants and mutations. Furthermore, it is unique among the most commonly used molecular tests in that the design includes an S gene target\*. If a sample with a variant that has the 69-70del is tested using the TaqPath COVID-19 test, it will result in an S gene dropout. Because of this, the test may signal the presence of the 69-70del and, potentially, B.1.1.7. For SARS-

CoV-2 sequencing we are using the targeted **Ion AmpliSeq™ SARS-CoV-2** Research Panel which can be readily integrated into our workflow downstream COVID-19 PCR testing and provides very high coverage, more than 99% of the SARS-CoV-2 genome, including all serotypes. This provides a fast and highly accurate consensus-level sequence determination."

The combination of Oncologica's expertise in genomic testing coupled to the Thermo Fisher Scientific SARS-CoV-2 test and sequence workflow provides a powerful testing capability to expedite the UK's return to work and to mitigate the risk of the spread of high-risk mutant variants in the population. ■

.....  
\*As of February 25, 2021

The TaqPath COVID-19 CE-IVD RT-PCR kit is labeled "For In vitro Diagnostic Use".

The Ion AmpliSeq SARS-CoV-2 Research Panel is labeled "For Research Use Only. Not for use in diagnostic procedures."

[www.oncologica.com](http://www.oncologica.com)  
<https://www.thermofisher.com/covid19mutations>



With innovative solutions and a reliable supply chain already helping meet the unprecedented demand for trusted SARS-CoV-2 testing, we continue to expand our high-quality solutions and accelerate innovation with urgency, addressing current and future challenges.

### The Applied Biosystems™ TaqMan® SARS-CoV-2 Mutation Panel Customisable and adaptable

**Features:**

- Customisable panel—choose from a menu of verified SNP assays to identify currently relevant SARS-CoV-2 mutations and adapt quickly as additional mutations and variants emerge
- Convenient—use your current real-time PCR instrumentation to conduct reflex analysis of SARS-CoV-2 samples
- Unique, streamlined workflow—combining gold-standard Applied Biosystems™ TaqMan® SNP Genotyping Assays with a one-step RT-PCR reaction enables you to go from RNA to results in just over an hour

Learn more at [thermofisher.com/mutationpanel](http://thermofisher.com/mutationpanel)

### Automated next-generation sequencing of the complete SARS-CoV-2 genome in a single day AmpliSeq SARS-CoV-2 Research Panel

**Features:**

- Complete workflow automation from nucleic acid to report for SARS-CoV-2 sequencing in a single day
- The Ion AmpliSeq™ SARS-CoV-2 Research Panel provides >99% coverage of the SARS-CoV-2 viral genome
- The workflow supports low-titer samples, allowing for high genomic coverage from as few as 20 copies of viral RNA
- Automated post-sequencing run analysis for variant annotation

Learn more at [thermofisher.com/ngs-coronavirus](http://thermofisher.com/ngs-coronavirus)



For Research Use Only. Not for use in diagnostic procedures. © 2021 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. TaqMan is a registered trademark of Roche Molecular Systems, Inc., used under permission and license. COL114073 0321

# ROLLING OUT HOPE: Mitigating Risk in Transporting The COVID-19 Vaccine



*Amy Shortman, Director of Product Marketing for Overhaul, looks at three key areas regarding the vaccine's transportation for which Overhaul have proudly been at the forefront of risk mitigation.*



*As the COVID-19 pandemic stretches into a second year, the past 12 months have exposed countless vulnerabilities and challenges, including supply chain disruptions.*

**That said, there are three key areas regarding the vaccine's transportation for which we have proudly been at the forefront of risk mitigation:** (1) time- and temperature-sensitive supply chain management, (2) supply chain security for theft, counterfeit prevention, and intellectual property and theft protection, and (3) real-time visibility for integrity, security, and quality.

#### **Managing Sensitive Supply Chains:**

Traditionally, the primary challenge is maintaining constant visibility into a shipment's temperature, which provides an audit trail to assure the product's quality, safety, and efficacy. The second challenge lies in maintaining quality control, and managing the costs associated with improperly handled products. While these challenges have been prevalent in the cold chain since its inception, the current global circumstances have made supply chain management even more convoluted. Time- and temperature-sensitive products require special considerations during transport, and transparency is key.

#### **Preventing Counterfeiting & Theft:**

Because of the unprecedented global demand, the security challenges of producing and

distributing COVID-19 vaccines cannot be understated. With everyone in desperate need, criminals are working tirelessly to introduce counterfeit products into the supply chain to turn a profit on black-market vaccines and actively seeking ways to steal from the supply chain's most vulnerable sections. Preparation and security are paramount to a successful vaccine roll-out, ensuring a proactive approach to mitigating risks through technology and real-time visibility.

#### **Offering Real-Time Visibility for Integrity, Security & Quality:**

The best-in-class option to successfully distribute COVID-19 vaccines securely, while maintaining their integrity, is with a digitized and connected supply chain network, supported by an easy-to-use platform that integrates all information and results in proactive, intelligent risk management and real-time visibility. When a deviation occurs, the real-time, risk-mitigation solution identifies the non-conformance and issues a corrective action to resolve the problem. By intelligently measuring what's happening in real-time against the Standard Operating Procedure, Overhaul protects, and the result is on-time, safe, and effective medicine delivery for patients. ■

*Because of the unprecedented global demand, the security challenges of producing and distributing COVID-19 vaccines cannot be understated.*



# HOW DOES INSURANCE HELP KEEP CLINICAL TRIALS SAFE?



*Hanna Beaumont, Client Partner, Science & Technology, Partners& provides an insight into the importance role that insurance has to play in this ever-changing environment.*

*The spotlight on clinical trials and what they mean to our everyday lives is perhaps now greater than ever before in modern history. With more and more activity taking place in this highly specialist and important field, risk management and insurance has an ever-increasing role to play.*

Clinical trials liability insurance will always have at its heart ‘putting it right’ for the patient or participant undergoing the trial if something goes wrong. However, there are many other interwoven strands to trials insurance, of which you may not be aware.

In seeking better ways to treat disease in humans, those engaged in the endeavour of Life Sciences must embrace risk on many levels. We must test rigorously to establish the safety and efficacy of each new drug, vaccine, medical device or surgical procedure.

Our human volunteers are protected with a framework of risk management, including rigorous controls and procedures – but discovery will always involve risk and, where mitigation reaches its limits, insurance must provide a safety net.

Alongside regulation and operational controls, it’s vital that a well-designed and robust insurance programme is in place to provide financial compensation for participants – and financial protection for the research organisations conducting these trials.

## How does clinical trials liability (CTL) insurance work?

Clinical trials carry obvious risk – for the patients or subjects, and also for other stakeholders in the process who may incur substantial liabilities if things go awry.

### CTL provides protection in two ways:

- Negligent harm to trial subjects - caused as a result of negligence, lack of due diligence/care on the part of the sponsor, investigator or CRO. The policy pays for legal costs and expenses, and compensation or “damages” awarded to the subject.
- Non-negligent harm (or “no-fault” compensation) - harm with no specifically identified cause, but likely to have arisen from the subject taking part in the research. Subjects in clinical trials will sometimes suffer non-negligent harm, with the expectation of being compensated despite there having been no negligence on the part of the sponsor or CRO.

CTL insurance is a vital piece of the risk mitigation jigsaw, and in many territories a legal requirement.

The universe of clinical trials is changing, as new non-pharma products come into the market with clinical application – from apps to medical robotics.



## How insurance is evolving with the trials landscape

These days, with the advances in “medtech”, clinical trials are not just about drug development (the development of a “new chemical entity”). They may involve the clinical testing of a new medical device or surgical procedure. And as the liabilities change, so too has the insurance evolved, offering additional lines of cover around risks and liabilities arising from contracts between trial parties (e.g., withheld fees). Policy (or multi-trial programme) periods have shifted to cover the whole length of the trial as opposed to an annual policy which has to be renewed every year mid-trial.

### CASE STUDY: software error

A software developer created a platform to upload data from medical imaging devices for use in a clinical trial. The platform enabled access to records across multiple trial sites. During the course of a change order update, an error was introduced into the code.

The developer resolved the issue, but multiple images had to be re-taken because of the coding error. The insurer was able to negotiate a favourable settlement before the issue went legal, to prevent any further costs. In fact, the professional indemnity cover sold alongside the CTL policy bore the cost.



### Selecting a CTL insurance broker

Connecting with the right advice can really make a difference. CTL is a unique and specialist area of insurance and as such, is only available from specialist insurers such as CFC, Chubb, CNA, Markel, QBE and Lloyd's of London. These policies are only accessible via an insurance adviser with the relevant expertise.

Before you purchase CTL insurance, make sure your adviser has:

- Genuine Life Science expertise in-house
- Lloyd's accreditation
- Speed of response – how quickly do they get back to your initial enquiry?
- Foreign and domestic capability
- Understanding of country-specific requirements

Good management of clinical trials should be based on a genuine partnership with your insurance adviser, and a culture of openness, trust and understanding. ■

With thanks to CFC Underwriting for their case study material



**Hanna Beaumont** FIRM  
Client Partner, Science & Technology  
**Partners&**  
07795 473071  
Hanna.beaumont@partnersand.com  
[www.partnersand.com](http://www.partnersand.com)

Partners& is the trading style of J N Dobbin Limited, which is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales. No. 00497227 Registered office: MRIB House, 25 Amersham Hill, High Wycombe, Buckinghamshire, HP13 6NU. Tel +44 (0) 1494 450011.

## Specialist insurance for the life science sector – advice that makes a difference

The UK is a world leader in the life science, technology, pharmaceutical and medical device industries. Companies are under pressure to innovate at pace, but working at the cutting edge can expose you to new risks and liabilities. **Getting the right insurance advice can make the difference.**

### What if:

- Your R&D materials are lost in a power outage?
- A data breach lands you in court?
- Your clinical trial goes pear-shaped?
- Your supply chain is compromised?

### Are you confident in your risk management arrangements?

The combined forces of **FOCUS Oxford Risk Management Ltd** and **Partners&** deliver expert risk protection advice to this unique sector.

We take a holistic approach – helping you to identify and understand your current and emerging risks so you can make informed decisions. With our ecosystem of trusted advisers, we keep abreast of the shifting sands of emerging risk, regulation, legislation, and compliance.

From university spin-outs and start-ups to multinational companies, we're here help you to map the pitfalls and tread confidently as your enterprise grows and changes.

And, if you need to make a claim, we'll stand shoulder to shoulder with you, getting you back on your feet fast and supporting you through the next challenge.

With offices across the UK, and in particular, Oxford, London and Cambridge, our team is well placed to meet the needs of OBN members wherever you are located.

“ Focused on building long-term, supportive relationships and business understanding. We couldn't ask for more from an insurance broker. ”

– Eric M, CEO, Life Science client



To find out how we can help you, talk to our team of experts:

01865 953 111  
[www.focusorm.co.uk](http://www.focusorm.co.uk)



Lifesciences | Biotech | Pharmaceuticals | E-health | Healthcare | IT | Medical technology | Bionanotechnology | Science Parks & Incubators | Investors  
FOCUS Oxford Risk Management Ltd is authorised and regulated by the Financial Conduct Authority, FCA Register Number: 773843, Registered in England & Wales No. 10428089, Registered address: 264 Banbury Road, Oxford, OX2 7DY. FOCUS is a trading name of FOCUS Oxford Risk Management Ltd.

# AN INTRODUCTION TO GEROSCIENCE:

## The truth about ageing



*Peter Hamley, Chief Scientific Officer, Samsara Therapeutics provides an introduction to Geroscience and debates 'Is longevity really a positive goal for humankind?'*

In 2013, several distinguished academics, including Guido Kroemer and Linda Partridge, wrote an article in *Cell* entitled “The Hallmarks of Ageing”. It would go on to be one of the most cited articles in biology in recent years, and act as a catalyst for a new area known as “geroscience”, the science of longevity and ageing. What’s special about the paper is that it approached ageing in the same way as the life sciences industry has traditionally approached disease: as something that can be understood, treated and - ultimately - cured.

The biggest risk factor in most major diseases – for example, cancer, neurodegeneration, heart disease – is age itself. The older you get the more susceptible you are to dying. It sounds obvious, but until recently people hadn’t thought much about ageing as an area to investigate therapeutically. But once you start to understand the biological mechanisms that contribute to the ageing process, you can begin not only to think about extending lifespan, but also to explore new avenues to treat hitherto intractable diseases. That’s why the “Hallmark” paper is so important. There are nine separate hallmarks described, ranging from epigenetics and DNA damage to nutrient responses and depletion of stem cells. In each area there are now many researchers engaged and increasingly biotechs and even big pharma are getting involved.

But there’s an elephant in the room - is longevity really a positive goal for humankind? An understandable reaction is to think that extending lifespan creates more problems than it solves. Surely, we don’t want everyone living into their hundreds? You might imagine a load of very frail and sick people needing care, and an unwelcome increase in population just as the world is running out of natural resources. But this is not the goal of geroscience. Most people in the field emphasise not lifespan but healthspan, defined as the age you start to suffer from a major life-threatening condition. As lifespans have increased over the last hundred years, there have been corresponding increases in all major diseases (other than infections). Increasingly, people spend their twilight years suffering from several of them. Of course, this is not how any of us would choose to spend our last years. But what if we could stay healthy for as long as possible? This would not only boost the quality of life, but also reduce the burden on our creaking healthcare

systems. And what moves the needle on global population is reproductive rate, not lifespan.

What’s truly exciting about this field, from a healthcare perspective, is the way the new thinking can be applied to specific diseases. This is a consequence not only of ageing being a risk factor, but also of a commercial reality: currently there’s no regulatory path to approval for an anti-ageing therapeutic. The reason is obvious – a clinical trial to show increased healthspan or lifespan would have to last many years to reach statistical significance. There are clever ideas to get round this issue – new biomarkers that measure biological age very accurately for example – and there are plans for the first FDA trial for longevity, using the diabetes drug metformin, which would create a trial design precedent with the approval authorities. But by far the best way to get a therapy based on geroscience research into humans is to first use it for a specific disease.

And there are now many companies who are working on this. The two “hallmarks” that are probably most advanced in clinical development are the areas of cellular senescence and proteostasis.

Senolytic drugs are compounds that remove senolytic cells from the body. Sometimes known as “zombie” cells, their numbers increase as you age. Instead of being cleared by the system via apoptosis, they persist and spew out toxins such as inflammatory cytokines. Thus, one of the first areas looked at for this approach is arthritis, an inflammatory disease of the joints. The companies in this area are led by Unity Biotechnology (backed by heavy weight investors such as Jeff Bezos and Peter Thiel) which recently failed in a trial in osteoarthritis. But this hasn’t dampened the enthusiasm of many earlier competitors,

.....  
*But what if we could stay healthy for as long as possible? This would not only boost the quality of life, but also reduce the burden on our creaking healthcare systems. And what moves the needle on global population is reproductive rate, not lifespan.*  
.....



such as Cleara, Rubido, Eternans, Dorian Therapeutics and Senolytic Therapeutics.

Proteostasis refers to the balancing act that the cell engages in to refresh itself, by removing toxins such as misfolded proteins. Many diseases are known to be at least partially caused by defects in the clean-up mechanisms engaged by the cell. For example, devastating neuronal disorders such as Alzheimer's and Parkinson's Disease are now thought by many scientists to be caused by the failure to clean up misfolded proteins, such as beta-amyloid and alpha-synuclein, from the neurons. The major clean up pathway is autophagy (from the Latin: self-eating), nature's way of treating cellular debris, and recycling it via the lysosome, the cellular waste disposal system. There are several companies looking for new molecules that induce autophagy, such as US biotechs Casma Therapeutics and Caraway Therapeutics, and Samsara Therapeutics (with labs in Oxford). Some compounds that (probably) work via autophagy are already in clinical trials, for example Anavex's Blarcamesine, which is showing early promise in both Alzheimer's and Parkinson's Disease.

Other "hallmarks" that have received a lot of attention are telomere shortening and stem cell exhaustion. When cells repeatedly divide the telomere protein length decreases, until the cell dies. It's like a ticking timebomb. And as we get older, our ability to produce stem cells, the precursor to all types of new cell in the body, reduces. So, could it be that supplementing stem cells, or stopping the telomeres from shortening, could make you live longer? These areas lack

clinical evidence and while there is some reputable research uncovering the fundamental biology there are also some, shall we say, less rigorous approaches. For example, you can sign up to an as yet non-existent clinical trial to boost your telomerase via gene therapy should you choose to ignore the connection between cell division and cancer. More realistic and promising is the possibility of discovering therapeutics that can influence the health of stem cells (for example the biotech Samumed with several clinical candidates).

There are now investment companies, such as Juvenescence, Life Biosciences, Apollo Health Ventures, Longevity Fund and others that are supporting and, in many cases, creating new longevity-themed biotechs, and many angel funds and family offices, often those with a particular personal reason for interest in the area, are increasingly involved. As the field chalks up clinical successes investment will surely increase further.

Finally, there are some intriguing theories about what the future holds for life extending therapies. For example, Aubrey de Gray, CEO of the SENS Institute and author of several books on longevity postulated that there is a "longevity escape velocity", and it has been claimed that this will be reached in perhaps 10-12 years from now. By this time, the theory goes, over a year's period humankind will have made sufficient life extending discoveries that would increase lifespan more than the year that had passed. In other words, the available medical intervention will always be one step ahead of our death and we will therefore live indefinitely, unless our demise is external, such as being run over by a bus. This sounds like science fiction, but there is a grain of truth to it – almost certainly lifespans will continue to increase, and we can be hopeful new therapeutics will be on the market in a decade that will significantly extend lifespan. Furthermore, it's tempting to speculate that different mechanisms will be synergistic: in other words combine two different drugs and you might be able to extend lifespan by a surprisingly large amount. For example, the record for extending worm lifespan, via a synergistic combination of effects, stands at 7.5 fold (around 400 worm years). And, true to the principles of geroscience, these 400-year-old worms appear to be as healthy as their younger cousins. Something to think about as you make plans for your retirement. ■

#### References:

Carlos López-Otín, Maria A. Blasco, Linda Partridge, Manuel Serrano, and Guido Kroemer (2013). The Hallmarks of Aging. *Cell*. 2013, 153(6): 1194–1217.

de Grey, ADNJ. (2004). Escape velocity: why the prospect of extreme human life extension matters now". *PLoS Biol*. 2(6): 723–726.

Koen Houthoofd, Bart P. Braeckman, Jacques R. Vanfleteren. (2004). The hunt for the record life span in *Caenorhabditis elegans*". *J Gerontol A Biol Sci Med Sci*. 59(5): B408–B410.



# ProcEurope

Saving you Time and Money

SAVE AN  
AVERAGE  
50% OFF  
LIST PRICE

Who we work with...



EER TRAVEL GROUP

Find out more...

E: [leepratley@proceurope.com](mailto:leepratley@proceurope.com)  
T: +44 (0) 778 8217 913  
W: [www.proceurope.com](http://www.proceurope.com)

In collaboration with



# THE BIOTECH BULLDOG



*2021 Life Science Forecast: No shortage of storm clouds, but brighter weather ahead*

*We are living in interesting times. As we move into Q2 2021 there are positive indications that the UK Life Sciences sector remains robust, with approximately £800m of new financing raised over Q1 alone (versus approximately £2.6bn over the whole of 2020). Perhaps expectedly, fundraising over Q1 2021 has reversed the 2020 anomaly, with over 75% of funds raised represented by unlisted private companies (versus just 45% over the whole of 2020). It's still too early to say how this will play out, but it looks like UK investors are following the 2018-19 pattern of putting more funding into privately-owned Life Science companies than their publicly listed counterparts. Over 2020 listed companies benefitted from investors backing more easily accessible publicly listed companies, many of which claimed (accurately or otherwise) to be addressing the threat of COVID-19.*

From conversations with City brokers there remains a lack of transparency regarding potential for UK Life Science companies in the public markets. Whilst AIM remains open for revenue generating companies (with the prospect of positive cash flow), the appetite for earlier stage, loss making firms remains relatively low, prompting one experienced broker to say that he didn't necessarily expect to see another UK (AIM) market for more traditional biotechnology firms 'in his lifetime'. Others remain more positive, with several pointing towards secondary exchanges as potentially providing a stepping stone to AIM. The more ambitious companies continue to target NASDAQ – perhaps not surprising given that the funds raised by Life Science IPOs on NASDAQ over 2020 averaged out at \$183m per new issue, versus just £71.5m for Life Science IPOs on AIM. Whilst Bears abound, highlighting a potential NASDAQ Life Science bubble, helped on its way by perhaps incomprehensible valuations for companies with even preclinical pipelines, US Life Science share prices continue to rise.

At some point valuations will ease (hopefully not crash), although broader brush macro-economics suggest at least short-term resilience. With a perceived reluctance for AIM to admit earlier stage companies, and Continental European exchanges not looking any more positive NASDAQ remains an alluring prospect for companies with the management bandwidth to vigorously prepare and execute the operational (i.e. 'boots on the ground' in the US) and financial (US reporting standards and the prospect of regular and sometimes lengthy investor roadshows) requirements. Amongst the UK financial community the jury

largely remains out in terms SPACs (Special Purpose Acquisition Companies). Their popularity has been extensively driven by the US hedge fund community, and other areas of concern include the longer-term objectives of SPAC sponsors, combined with the potential hurdles associated with subsequent 'de-SPACing'. It seems likely that the traditional benefits of the IPO process, in terms of

*The more ambitious companies continue to target NASDAQ – perhaps not surprising given that the funds raised by Life Science IPOs on NASDAQ over 2020 averaged out at \$183m per new issue, versus just £71.5m for Life Science IPOs on AIM.*



Look out for the Biotech Bulldog's report in our next issue of CONNECT



establishing a company in a listed market, with the support of advisers, market makers and brokers may be less than optimal for those companies seeking SPAC-based access to the US markets.

As if there was not already enough uncertainty, there remain a number of additional drivers of potential volatility on the horizon. The proposed London listing of Oxford Nanopore, although a 'positive headline' for the UK sector, has raised concerns about the loss of credibility for the UK sector overall, should proposed valuations fail to be supported post-IPO. In the UK the spectres of British Biotech, Circassia and others continue to cast long shadows over a relatively non-specialist public market investor base. Moreover, given the relatively small size and fragile nature of the UK market, memories of 'sinking flagships' tend to be long lasting (whereas in the US, for example, the sheer critical mass of the industry means that failures are quickly superseded by more positive stories). We must hope that inflated valuation does not trump the longer-term prospects for the wider market. Similarly the February 2021 creation of Woodford Capital Management has raised fears and even the odd hackle. The Channel Islands and the Cayman Islands have been mooted as a new

*Whilst some will continue to successfully list on NASDAQ, and doubtless others will struggle to list on AIM, the likelihood of acquisition, which traditionally have generated higher valuations (versus IPOs) remain high.*

base, although the short-term objectives of the new company appears to be focused on advice regarding its historic assets rather than the launch of a new fund per se. Whilst it would be churlish not to wish the new Woodford venture the best of luck, it is worth remembering that single investors, with widespread holdings across a single (and relatively small) sector, will always disproportionately impact valuations, and raise the risk of volatility.

Nevertheless, against this somewhat stormy and unpredictable outlook a number of positives thankfully remain. Firstly, the macro-economic impact of slowly driving down COVID-19 infection rates should prove positive for the capital markets, which will play a critical role in driving economic recovery. Secondly, the quality of UK Life Sciences remains unsurpassed, at least on a per capita basis. Perhaps most importantly, the historic core value drivers of the UK Life Science market, in terms of privately owned companies, are once again taking centre stage. Whilst some will continue to successfully list on NASDAQ, and doubtless others will struggle to list on AIM, the likelihood of acquisition, which traditionally have generated higher valuations (versus IPOs) remain high. The fundamentals remain solid, as do the prospects for value accretion and liquidity events for shareholders. For UK Life Science companies that plot and navigate their paths towards liquidity - albeit with the appropriate level of diligence and agility - the outlook for 2021 remains perhaps surprisingly bright. However, 2021 will not be a year for management teams to rest on their laurels. ■



The 'Roadmap for Growth' Life Sciences Event



**SPONSOR, EXHIBIT, ATTEND**  
OXFORD 23 SEPTEMBER 2021

Organised by



[www.bioforward.co.uk](http://www.bioforward.co.uk)

@BioForwardUK

#BioForward

# OBN Members Directory

OBN's Corporate Membership of 400-plus organisations includes many R&D companies (therapeutic, medical technology and diagnostics) as well as an extensive range of contract research (CRO) and manufacturing (CMO) organisations, companies in the associated industries and specialist suppliers.

The listing below shows our Member companies arranged by sector.

## Therapeutics Discovery and Development

### Absynth Biologics

[www.absynthbiologics.co.uk](http://www.absynthbiologics.co.uk)

Discover and develop vaccines and antibodies to prevent and treat bacterial infections

### Activatec

[www.activatec-bi.com](http://www.activatec-bi.com)

Focus on the evaluation of processes for the manufacture of active biobased compounds and ingredients for nutraceutical and cosmetics products from currently unused and low-value organic sources

### Adaptimmune

[www.adaptimmune.com](http://www.adaptimmune.com)

A clinical-stage biopharmaceutical company focused on the development of novel cell-based cancer immunotherapy products

### Antikor Biopharma

[www.antikor.co.uk](http://www.antikor.co.uk)

Developing innovative antibody fragment-drug conjugates for improved tumours treatments. The company's proprietary lysine-based conjugation platform, OptiLink™, enables high payload loading of the antibody fragment, more effective penetration of tumours and rapid clearance from normal tissue

### Antiverse

[www.antiverse.io](http://www.antiverse.io)

Developing an AI driven antibody discovery platform to predict antibody-antigen binding and provide antibody drug candidate selection

### Arecor

[www.arecor.com](http://www.arecor.com)

Developing a portfolio of proprietary products that will enable improved treatments for diabetes via the reformulation of approved proteins and peptides

### Ascension Healthcare

[www.ascension.co.uk](http://www.ascension.co.uk)

A clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for the treatment of haemophilia and osteoarthritis

### BenevolentAI

[www.benevolent.ai](http://www.benevolent.ai)

Focus on bringing together artificial intelligence technology and scientific research to enable more rapid creation of better medicines

### Bioarchitech

[www.bioarchitech.com](http://www.bioarchitech.com)

Developing oncolytic viruses for cancer treatment

### Blueberry Therapeutics

[www.blueberrytherapeutics.com](http://www.blueberrytherapeutics.com)

A drug discovery and development company, engaged in the development of therapies to treat infectious and inflammatory diseases

### Carocell Bio

[www.carocellbio.com](http://www.carocellbio.com)

Carocell Bio is developing novel combination medicines for serious inflammatory conditions, including atopic dermatitis, inflammatory bowel disease and burns

### Celleron Therapeutics

[www.cellerontherapeutics.com](http://www.cellerontherapeutics.com)

Developing new cancer drugs, Celleron's preclinical pipeline consists of a series of target enzymes involved in control of epigenesis with key roles in cancer biology

### CHAIN Biotechnology

[www.chainbiotech.com](http://www.chainbiotech.com)

Focused on the development of its Clostridia-based proprietary CADD™ platform for delivery of therapeutics and vaccines to the lower gastrointestinal tract

### CN Bio Innovations

[www.cn-bio.com](http://www.cn-bio.com)

Develops human organ-on-a-chip technologies and devices that enable the formation of miniature models of human organs which can be used in the drug discovery and development process

### Creoptix AG

<https://www.creoptix.com/>

Provides technologies and expertise for gathering data on a wide range of biological interactions including to detect and quantify biological interactions in real-time, providing both binding affinity and kinetics

### Crescendo Biologics

[www.crescendobiologics.com](http://www.crescendobiologics.com)

An oncology-focused drug discovery and development company using its proprietary Humabody™ VH technology to develop novel targeted T-cell engaging therapeutics

### Cumulus Oncology

<https://www.cumulusoncology.com/>

Cumulus is developing novel anti-cancer therapies

### CytoSeek

[www.cytoseek.uk/](http://www.cytoseek.uk/)

CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing

### DJS Antibodies

[www.djsantibodies.com](http://www.djsantibodies.com)

Discovery and development of functional antibodies to GPCRs

### Eli Lilly & Company

[www.lilly.co.uk](http://www.lilly.co.uk)

A research based global pharmaceutical company with diverse interests including oncology, neuroscience and diabetes and related complications

### Enara Bio

[www.enarabio.com](http://www.enarabio.com)

Exploiting novel insights into the expression of human endogenous retroviruses in different cancers to develop a pipeline of first-in-class cancer vaccines

### Enesi Pharma

[www.enesipharma.com](http://www.enesipharma.com)

A clinical-stage pharmaceutical company focusing on the development of solid dose vaccines and other injectable solid dose drug-device combination products

### Epsilogen (formerly IGEM Therapeutics)

<https://igemtherapeutics.com>

An immuno-oncology company focused on developing immunoglobulin E (IgE) antibodies to treat cancer. The lead product for ovarian cancer is in Phase 1/2

### e-Therapeutics

[www.etherapeutics.co.uk](http://www.etherapeutics.co.uk)

A drug discovery company with a proprietary computational drug discovery platform based on advances in network pharmacology and chemical biology

### Evovx Therapeutics

[www.evovxtherapeutics.com](http://www.evovxtherapeutics.com)

A biotechnology company focused on harnessing and engineering the natural delivery capabilities of exosomes to develop an entirely new class of therapeutics

### Exonate

[www.exonate.com](http://www.exonate.com)

Developing drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need with an immediate focus on alternative splicing of VEGF to treat wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME)

### Exscientia

[www.exscientia.ai](http://www.exscientia.ai)

Applying its proprietary AI platform to big data to accelerate the drug discovery and design process

### Fast Biopharma

[www.fastbiopharma.com](http://www.fastbiopharma.com)

Established to address new targets in immuno-oncology. The company's lead product is an optimised antibody against a key oncology target

### Grey Wolf Therapeutics

[www.greywolftherapeutics.com](http://www.greywolftherapeutics.com)

Develops immunotherapies that illuminate non-responsive tumors for destruction by the immune system. The company is developing small molecules to target ERAP1 and 2, targets of growing academic interest for multiple cancers

### GyreOx Ltd

[www.gyreox.com](http://www.gyreox.com)

GyreOx's proprietary discovery platform creates unique 'Gyrocycle' highly modified macrocyclic peptides, which combine the target-engagement power of biologics with the cell-entry ability of small molecules

**Haemostatix**[www.haemostatix.com](http://www.haemostatix.com)

Developing and commercialising active clotting agents/haemostats for the control of bleeding

**Hairclone**[www.hairclone.me](http://www.hairclone.me)

Working to development hair rejuvenation and regeneration treatments

**HOX Therapeutics**[www.hoxtherapeutics.com/](http://www.hoxtherapeutics.com/)

Developing novel treatments for cancer through targeting HOX family proteins which frequently have aberrant biological activity in tumours

**ILC Therapeutics (formerly Alfacyte)**<https://www.ilctherapeutics.com/>

Focused on developing new treatments for cancer, atopic dermatitis and psoriasis using novel peptides that modulate the innate immune system

**Imophoron**[www.unitdx.com/novel-vaccine-technology-interview-fred-garzoni-imophoron](http://www.unitdx.com/novel-vaccine-technology-interview-fred-garzoni-imophoron)

Developing a novel vaccine platform for use on emerging infectious diseases. The platform is based on a single component of the human Adenovirus that spontaneously forms a superparticle, the ADDomer

**Innaxon Therapeutics**[www.innaxon.com](http://www.innaxon.com)

Working in the area of innate immunity and has lead products in cancer and inflammatory disease. These are the Toll-like Receptor 4 (TLR4) agonists (Dendrophilin® and Novo-Pyrexal®) and an in-licensed small molecule inhibitor (an IAXOTM compound)

**Ipsen Bioinnovation**[www.ipsen.com/uk/](http://www.ipsen.com/uk/)

A global pharma company with three main areas of focus: oncology, neurosciences and rare diseases

**Kalvista Pharmaceuticals**[www.kalvista.com](http://www.kalvista.com)

A pharmaceutical company focused on the discovery, development and commercialisation of small molecule protease inhibitors as new treatments for hereditary angioedema (HAE), diabetic macular edema (DME), and other plasma kallikrein-associated diseases

**Karus Therapeutics**[www.karustherapeutics.com](http://www.karustherapeutics.com)

Designs and develops small-molecule drugs that combine targeted therapy and immunotherapy activity for the effective treatment of a diverse range of solid and hematological cancers

**Locate Bio**[www.locatetherapeutics.com](http://www.locatetherapeutics.com)

A specialist regenerative medicine and device company which has developed TAOS™, a patented platform polymer technology with multiple medical applications

**Macrophage Pharma**[www.macrophagepharma.com](http://www.macrophagepharma.com)

an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses

**metaLinear**[www.metaLinear.co.uk](http://www.metaLinear.co.uk)

metaLinear is active in discovering novel targets for anti-bacterial drugs and antibiotic re-sensitisers through proteome engineering

**MiroBio**<http://www.mirobio.com/>

A 2019 OUI spinout working on treatments for autoimmune and inflammatory disorders

**Mironid**<https://www.mironid.com/>

Developing new medicines for degenerative kidney diseases, chronic inflammatory diseases and cancer

**Nanomerics**[www.nanomerics.com](http://www.nanomerics.com)

Mainly develops drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides using proprietary pharmaceutical nanotechnology

**NanOptima**

A biotechnology startup based in Alderley Park BioHub developing novel formulations that include peptidic hydrogel and/or nanoparticle technologies to improve ophthalmic drug delivery

**NestTeck**[www.biocity.co.uk/company/nestteck/](http://www.biocity.co.uk/company/nestteck/)

Developing environmentally responsible antimicrobial and insecticide technologies for a range of industrial and consumer applications, including the veterinary, industrial and healthcare sectors

**Neuro-Bio**[www.neuro-bio.com](http://www.neuro-bio.com)

Involved in drug discovery and development in the area of degenerative brain disease. Their unique strategy has produced a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE. T14 is neurotoxic in the adult brain and published data shows it to be a potential key driver of neurodegeneration

**NeurocentRx Pharma**[www.neurocentrx.com](http://www.neurocentrx.com)

Focused on developing medicines to alleviate severe and chronic neuropathic pain experienced by cancer patients

**Novo Nordisk**[www.novonordisk.com](http://www.novonordisk.com)

A global pharma with diverse interests particularly in the area of diabetes and associated diseases

**Nucleome**[www.nucleome.com](http://www.nucleome.com)

Developing therapeutics based on a proprietary 3D nuclear architecture and AI powered computational genomics drug discovery platform

**NuVision Biotherapies**[www.nu-vision.co.uk](http://www.nu-vision.co.uk)

Established to commercialise biotherapies for treating 'front of the eye' disease and trauma

**Ochre Bio**[www.ochre-bio.com](http://www.ochre-bio.com)

Developing genomic medicines to reprogram liver metabolism

**OMass Therapeutics**[www.omass.com](http://www.omass.com)

Focused on structural mass spectrometry to discover novel medicines

**Orbit Discovery**[www.orbitdiscovery.com](http://www.orbitdiscovery.com)

Utilises its proprietary display platform to identify robust peptide drug candidates for internal industry drug discovery programs and via collaborative research

**Ossianix**[www.ossianix.co.uk](http://www.ossianix.co.uk)

Developing biotherapeutic products based on the single domain VNAR antibody from the shark. Current programs focus on autoimmunity, neurodegeneration, ALS, pain and botulism

**Oxford BioMedica**[www.oxb.com](http://www.oxb.com)

A gene and cell therapy company focused on developing life changing treatments in the areas of oncology, ophthalmology and CNS disorders

**Oxford Stemtech**<https://www.oxfordstemtech.com/>

Developing innovative approach to produce induced pluripotent stem cells for research

**Oxford Vacmedix**[www.oxfordvacmedix.com](http://www.oxfordvacmedix.com)

Developing therapeutic agents for the treatment of cancer based on Recombinant Overlapping Peptides (ROPs)

**Oxgene**<https://www.oxgene.com/>

Developing a range of technologies to enable precise and robust mammalian cell engineering to enable more rapid development of gene therapies, antibody-based therapeutics and CRISPR / gene editing

**OxSonic Therapeutics**[www.oxsonics.com](http://www.oxsonics.com)

Developing an ultrasound based platform to enhance the delivery of anti-cancer agents to tumours by disrupting the structure of the tumour

**OxStem**[www.oxstem.co.uk](http://www.oxstem.co.uk)

A drug discovery company with the vision of developing in-situ cell re-programming therapies to treat dementia, heart failure, macular, diabetes and oncology

**Oxular**[www.oxular.com](http://www.oxular.com)

Developing novel retinal treatments engineered to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases

**Pathios Therapeutics**[www.pathios.com](http://www.pathios.com)

Pathios Therapeutics is an early-stage drug discovery company pursuing novel small-molecule drugs that target acid-sensing GPCRs on cells of the adaptive and innate immune systems

**Pedanius Therapeutics**[www.pedaniustherapeutics.com](http://www.pedaniustherapeutics.com)

Developing RNAi therapies for Gram-negative bacterial infections

**PepGen**

Developing cell-penetrating peptides for treatment of muscular dystrophies

**PharmaKrysto**[www.pharmakrysto.co.uk](http://www.pharmakrysto.co.uk)

Developing new therapeutics to save kidneys and prevent pain in people with cystinuria

**Phylo Bioscience**[www.phylos.bio](http://www.phylos.bio)

A plant biotech company aiming to apply genomics and statistics to revolution the future of cannabis

**Platelet Services**[www.plateletservices.com](http://www.plateletservices.com)

Provides products and services for platelet function testing which is useful for diagnosis of abnormal bleeding and to monitor platelet function in those who are at-risk of cardiovascular events

**Polymaths AI**[twitter.com/polymathsai](https://twitter.com/polymathsai)

An Oxford University spinout developing and providing AI augmented model-informed drug discovery and development services



**Precision Medicines**[www.precimed.com](http://www.precimed.com)

Focuses on in-licensing innovative drug candidates which are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use

**Precision NanoSystems**[www.precisionnanosystems.com](http://www.precisionnanosystems.com)

Working on the discovery, development, and manufacture of novel nanoparticle medicines

**ProFactor Pharma**[www.profactorpharma.com](http://www.profactorpharma.com)

Develops, commercialises, and supplies recombinant blood factors for the treatment of haemophilia

**PsiOxus Therapeutics**[www.psiexus.com](http://www.psiexus.com)

Focused on discovering and developing gene-based immunology treatments for solid tumors using its proprietary intravenously administered T-SiGN virus platform

**Redx Pharma**[www.redxpharma.com](http://www.redxpharma.com)

Focuses on the development of small molecule therapeutics in particular for cancer and fibrosis

**Replimune**[www.replimune.com](http://www.replimune.com)

Develop novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released

**Rexgenero**[www.rexgenero.com](http://www.rexgenero.com)

Developing autologous cells therapies with a focus on peripheral vascular disease

**Sarepta Therapeutics**[www.sarepta.com](http://www.sarepta.com)

Developing breakthrough therapies to treat genetic disease with a focus on muscular dystrophies and Charcot-Marie-Tooth

**Scancell**[www.scancell.co.uk](http://www.scancell.co.uk)

Scancell is focused on developing a pipeline of DNA-based cancer immunotherapies that encode a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells

**Silence Therapeutics**[www.silence-therapeutics.com](http://www.silence-therapeutics.com)

An siRNA company with interests in diverse areas including beta thalassemia, myelodysplastic syndrome and cardiovascular disease

**Sitryx Therapeutics**[www.sitryx.com](http://www.sitryx.com)

A biopharmaceutical company focused on regulating cell metabolism to develop disease modifying therapeutics in immuno-oncology and immuno-inflammation

**Sporegen**<http://sporegen.com/>

Sporegen is working on a number of products including the development of vaccines based on Bacillus subtilis

**Summit Therapeutics**[www.summitplc.com](http://www.summitplc.com)

Focus on the discovery, development and commercialisation of novel medicines for bacterial diseases

**Theolytics**[www.theolytics.com](http://www.theolytics.com)

A start-up biotech company focused on development of oncolytic viral therapies

**TopiVert Pharma**[www.topivert.com](http://www.topivert.com)

Developing next-generation, Non-Systemic Kinase Inhibitors (NSKIs) as novel medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye

**Twist Bioscience**[www.twistbioscience.com](http://www.twistbioscience.com)

A synthetic biology company that manufactures and sells synthetic DNA-based products.

**UCB Pharma**[www.ucbpharma.co.uk](http://www.ucbpharma.co.uk)

Dedicated to the research, development and commercialisation of medicines with a focus on the diseases of the central nervous system (CNS) and immunology disorders

**Vaccines Manufacturing & Innovation Centre**[www.vmicuk.com](http://www.vmicuk.com)

VMIC is a not for profit research company within the national scientific infrastructure providing strategic vaccine development and manufacturing capability

**Vaccitech**[www.vaccitech.co.uk](http://www.vaccitech.co.uk)

Develop leading T cell-inducing vaccine products to improve global health. It is engaged in Phase 2 clinical programs for universal influenza and prostate cancer, Phase 1 for MERS, and preclinical programs for 3 other therapeutic infectious diseases indications

**Valo Therapeutics**[www.valotx.com](http://www.valotx.com)

Developing cancer therapies using the PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) platform which combines two clinically proven cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vaccine, to take advantage of the best features of both technologies

**Vertex Pharmaceuticals (Europe)**[www.vrtx.com](http://www.vrtx.com)

Focused on the discovery and development of small molecule drugs for serious diseases. Has a very strong pipeline in cystic fibrosis but also has interests in pain and haemoglobinopathies

**Viatem**[www.birminghamresearchpark.co.uk/tenants/viatem-ltd](http://www.birminghamresearchpark.co.uk/tenants/viatem-ltd)

Aiming to develop the potential of peptimem, a short peptide, that plays a role in controlling inflammation

**ConserV Bioscience**[www.conservbio.com](http://www.conservbio.com)

A late-stage vaccine development company focused on advancing safe and effective vaccines that protect against endemic and emergent infectious diseases

**Samsara Therapeutics**[www.samsaratherapeutics.com](http://www.samsaratherapeutics.com)

Developing therapeutics for diseases of aging, neurodegeneration and rare genetic disease

**Evgen Pharma Plc**[www.evgen.com](http://www.evgen.com)

Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation

**Ferryx**[www.ferryx.com](http://www.ferryx.com)

Live biotherapeutic products for the treatment of gut inflammation

**coding.bio**[www.coding.bio](http://www.coding.bio)

Accelerating development of cell therapies through better approaches to biomolecule selection

**Argonaute RNA**[www.argonauterna.com](http://www.argonauterna.com)

Developing safe and reliable methods or temporarily silencing target genes in different tissue or cells

**Stark Labs**[www.starklabs.eu](http://www.starklabs.eu)

STARLABS was the first team to develop an alternate method for the depletion of senescent cells in age-related pathologies using immunotherapy. We believe that selective senescent cell destruction is the key to achieving successful clinical outcomes which will result in a longer lifespan in good h

**LUNAC Therapeutics**[www.lunactherapeutics.com](http://www.lunactherapeutics.com)

Developing advanced life-saving anticoagulants with minimal risk of bleeding

**Bayer AG**[www.pharma.bayer.com](http://www.pharma.bayer.com)

Bayer is a long-established global pharmaceutical company with diverse interests including pharmaceuticals, consumer health and crop sciences

## Medtech

**Abingdon Health**[www.abingdonhealth.com](http://www.abingdonhealth.com)

A diagnostics group, working across multiple industry sectors, developing, manufacturing and commercialising lateral flow immunoassay tests and reader system internally and for contract customers

**Accentus Medical**[www.accentus-medical.com](http://www.accentus-medical.com)

Develop novel surface technologies to address the challenges of implantable medical device design and performance

**Accunea**[www.accunea.com](http://www.accunea.com)

A point-of-care diagnostics company which combines a small bedside bioanalytical system with artificial intelligence to enable the continuous and real-time monitoring of a patient's kidney function

**Advanced Molecular Diagnostics**[www.am-diagnostics.co.uk](http://www.am-diagnostics.co.uk)

A molecular diagnostics company that develops, manufactures and supplies molecular diagnostic instruments, kits and consumables

**Anaphite**[www.anaphite.com](http://www.anaphite.com)

Developing a nanomaterial ('Anaphite') that is a combination of graphene and anastase. The nanocomposite is a photocatalyst that can be used for air purification and battery technology

**APA Parafricta**[www.parafricta.com](http://www.parafricta.com)

A wound care company which markets a range of skincare products made from its proprietary, low-friction fabric, Parafricta®

**Base Genomics Limited**[www.basegenomics.com](http://www.basegenomics.com)

Developing the proprietary TAPS platform that generates both genetic and epigenetic information at base resolution. Multiple applications in diagnostics, patient monitoring and many other areas.

**Blue Earth Diagnostics**[www.blueearthdiagnostics.com](http://www.blueearthdiagnostics.com)

A molecular imaging diagnostics company focused on the development and commercialisation of novel PET imaging agents to inform clinical management and guide care for cancer patients

**Cambridge Respiratory Innovations (CRiL)**[www.criltd.co.uk](http://www.criltd.co.uk)

Develop innovative medical devices to diagnose and manage respiratory conditions

**Carbometrics**[www.carbometrics.com](http://www.carbometrics.com)

Using proprietary Biomimetic Glucose Binding Molecules (GBM) to develop a new glucose sensor chemistry that will enable market-leading Continuous Glucose Monitors (CGM)

**Cernotas**[www.cernotas.com](http://www.cernotas.com)

Developing a new microbiology testing platform capable of determining the presence of microorganisms

**DynamX Medical**[www.dynamxmedical.com](http://www.dynamxmedical.com)

Developing a diagnostic system that distinguishes between cancerous and pre-cancerous tissues biopsies. The system combines commercially-available hardware with their patent-pending data analysis method to provide a rapid system for screening biopsies at the point-of-care

**Edinburgh Molecular Imaging**[www.edinimage.com](http://www.edinimage.com)

A clinical phase biotechnology company focused developing imaging agents that can be used to detect diseased tissue in real-time with the potential for use during interventional procedures including surgery

**Endomag**[www.endomag.com](http://www.endomag.com)

Produce diagnostic technology for more effective breast cancer localisation within breast tissue and sentinel lymph nodes thereby help women with breast cancer avoid surgery when it isn't needed, and experience better outcomes when it is

**Enlight Medical**[www.enlightmedical.com](http://www.enlightmedical.com)

Translate complex scientific ideas into eye-catching, easy-to-understand 3D animations, using state-of-the-art computer-generated imagery and virtual reality tools, to help you communicate the science behind your brand to broader audiences

**FluoretiQ**[www.fluoretiq.com](http://www.fluoretiq.com)

Developing a rapid diagnostic platform for detection of bacteria at the PoC. Their platform is based on advances in glycan chemistry and quantum optics

**Future Genetics**[www.futuregenetics.co.uk](http://www.futuregenetics.co.uk)

A non-profit focused on the discovery and development of disease biomarkers in areas of unmet clinical need

**Genomics plc**[www.genomicsplc.com](http://www.genomicsplc.com)

A genome analysis company building analytical platforms for optimising genome sequencing and integrating DNA data with diverse biological information to enable better discovery of new drug targets and to deliver precision health

**GM Scientific**[www.linkedin.com/company/gm-scientific/about/](http://www.linkedin.com/company/gm-scientific/about/)

Specialises in the distribution and marketing of innovative healthcare products

**Hutano Diagnostics**[www.linkedin.com/company/hutano-diagnostics/](http://www.linkedin.com/company/hutano-diagnostics/)

A start-up developing a diagnostic and surveillance platform for diseases caused by emerging and dangerous pathogens which cause recurring epidemics in Africa

**Inivata**<https://www.inivata.com/>

A global clinical cancer genomics company. Its InVision® platform unlocks essential genomic information from a simple blood test to help realise personalised care for cancer patients

**Intelligent OMICS**<http://www.intellomx.com/>

Using an in house data analysis algorithm to identify patterns in healthcare datasets to find new disease markers and drivers of disease pathways that will lead to new diagnostic tools and targeted therapies

**Invizius**<https://www.invizius.com/>

Developing a coating for kidney dialysis membranes that prevents activation of the immune system and its undesirable effects on the patient

**Iota Sciences**[www.iotasciences.com](http://www.iotasciences.com)

Are pioneering the development of technologies that facilitates the rapid shaping of liquids on surfaces used to maintain and analyse cells, i.e. polystyrene and glass

**Isansys Lifecare**[www.isansys.com](http://www.isansys.com)

Developing and commercialising wireless monitoring devices and systems for real time and predictive indications of patient status in the hospital and home setting

**Manchester BIOGEL**[www.manchesterbiogel.com](http://www.manchesterbiogel.com)

Developing biocompatible and biodegradable graft materials that provide the ideal matrix for implanted cells to carry out tissue repair and regeneration

**Medherant**[www.medherant.co.uk](http://www.medherant.co.uk)

A clinical-stage company developing drug-in-adhesive patch products for pain and CNS diseases based on their TEPI® technology in combination with already approved drugs

**Marker Diagnostics**

A biotech startup developing microRNA biomarkers for use in molecular neuroscience

**Momentum BioScience**[www.momentumbio.co.uk](http://www.momentumbio.co.uk)

Develops rapid tests for critically-important clinical specimens within the hospital microbiology laboratory

**Newrotex**[www.newrotex.com](http://www.newrotex.com)

Newrotex has developed a silk-based nerve conduit to treat peripheral nerve injury (PNI). The 'off-the-shelf' device allows immediate treatment for patients who have suffered injury through trauma or cancer surgery, without any of the associated risks of the current gold-standard treatment of autografts

**NuNano**[www.nunano.com](http://www.nunano.com)

A UK-based company specialising in the design and manufacture of probes for atomic force microscopy and cantilever-based sensor devices

**Onca XT**[www.oncaxt.com](http://www.oncaxt.com)

Developing a unique type of blood test for cancer which, used in conjunction with existing methods of screening and diagnosis, could improve their accuracy of diagnosis

**Oncimmune**<https://oncimmune.com/>

Oncimmune is developing early cancer detection technologies for more effective disease management

**Orthox**[www.orthox.co.uk](http://www.orthox.co.uk)

Developing a range of novel orthopaedic products for the repair of knee cartilage formed from FibroFix™, a patented, biomaterial with a molecular structure, strength and resilience that emulates human knee cartilage

**Oxford Cancer Biomarkers**[www.oxfordbio.com](http://www.oxfordbio.com)

Developing a suite of drug-specific companion diagnostic tests using its predictive biomarker technologies CancerNav®

**Oxford Endovascular**[www.oxfordendovascular.com](http://www.oxfordendovascular.com)

A medical device company developing a next generation flow-diverter for the minimally invasive treatment of intracranial aneurysms which cause death or disability due to brain haemorrhage

**Oxford Gene Technology**[www.ogt.co.uk](http://www.ogt.co.uk)

Provides genetics research solutions to clinical and academic research institutions

**Oxford Immunotec**[www.oxfordimmunotec.com](http://www.oxfordimmunotec.com)

A global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology

**Oxford Nanopore Technologies**[www.nanoporetech.com](http://www.nanoporetech.com)

Developing a new generation of nanopore-based electronic systems for analysis of single molecules, including DNA, RNA and proteins

**Psyros Diagnostics**[www.psyros.com](http://www.psyros.com)

Developing an ultra-sensitive point-of-care diagnostic technology platform

**Renovos Biologics**[www.renovos.co.uk](http://www.renovos.co.uk)

Commercialising the research undertaken at the University of Southampton on skeletal stem cells, translational orthopaedic research and materials for tissue repair

**Rosa Biotech**[www.rosabio.tech](http://www.rosabio.tech)

Developing new sensing devices that mimic the properties of the olfactory systems of mammals. The key components are self-assembling peptide barrels capable of binding a huge range of analytes and these are linked to a colorimetric measurement system

**Safeguard Biosystems Holdings**[www.sgbio.com](http://www.sgbio.com)

Commercialising molecular diagnostic technologies and tests for mass surveillance and selective screening for pathogens and other agents for agriculture, food safety, genetic screening and human health applications

**Sense Biodetection**[www.sense-bio.com](http://www.sense-bio.com)

Developing a range of point of care diagnostics

**SeraScience Limited**<https://www.abingdonhealth.com/medical-diagnostics/seralite/>

SeraScience operates as a part of Abingdon Health. They work in the diagnostic space and have a lead product 'Seralite' for detection of multiple myeloma

**Spintex Engineering**[www.spintex.co.uk](http://www.spintex.co.uk)

Spintex, a spin out from the University of Oxford, manufactures pure and tough silk fibres and materials for medical devices and regenerative medicine

**The Electrospinning Company**[www.electrospinning.co.uk](http://www.electrospinning.co.uk)

Design, develop and manufacture materials for use in regenerative devices and in 3D cell culture

**Ultromics**[www.ultromics.com](http://www.ultromics.com)

Developing an AI-driven software platform that provides increased diagnostic capabilities to echocardiography equipment to improve the diagnosis of coronary heart disease

**VivoPlex Medical**[www.vivoplex.com](http://www.vivoplex.com)

Developing an innovative monitoring device to measure dissolved oxygen (DO), pH and temperature in the uterus of women seeking medical help to improve their fertility

**Yourgene Health**[www.yourgene-health.com](http://www.yourgene-health.com)

Molecular diagnostics company providing a range of gene testing and analytical services to a range of markets

**Presymptom Health Limited**<https://www.presymptom.com/>

Developing life-saving diagnostic technology to detect sepsis earlier than current technologies and which will be able to significantly improve outcomes

**AccendoLab Limited**[www.accendolab.co.uk](http://www.accendolab.co.uk)

A diagnostics company operatin an approved Covid-19 testing laboratory

**Other biotechnology****Azotic Technologies**[www.azotictechnologies.com](http://www.azotictechnologies.com)

Their natural nitrogen fixing technology, which is based on a food grade bacteria, provides a sustainable solution to fertiliser overuse and nitrogen pollution

**Folium Food Science**[www.foliumscience.com](http://www.foliumscience.com)

Developing 'Guided Biotics' to alter the composition of complex microbiomes. Applications envisaged include removal of undesirable bacteria from animals and plants and from the environment and food

**Glaia Limited**[www.glaia.co.uk](http://www.glaia.co.uk)

Aiming to enhance agricultural productivity and reduce pressure on natural resources by optimising the performance of plants

**Green Biologics**[www.greenbiologics.com](http://www.greenbiologics.com)

A renewable chemicals company focused on developing and delivering new green alternatives for everyday products providing clients with more sustainable products compared to petroleum-based alternatives

**Jellagen**[www.jellagen.co.uk](http://www.jellagen.co.uk)

Offer high grade native collagen sourced from jellyfish. This is applicable for tissue engineering, regenerative medicine, stem cell research and a wide variety of cell culture application

**MOA Technology**[www.moa-technology.com](http://www.moa-technology.com)

Aim to discover the next generation of sustainable herbicide chemistries with new modes of action from both natural and synthetic sources

**Myconeos**[www.myconeos.com](http://www.myconeos.com)

Production of fungal spores for use in the food industry

**Worn Again Technologies**[www.wornagain.co.uk](http://www.wornagain.co.uk)

Pioneering polymer recycling technology that can separate, decontaminate and extract polyester polymers, and cellulose from cotton, from non-reusable textiles and PET bottles and packaging and turn them back into new textile raw materials as part of a continual cycle

**Zentraxa**<https://zentraxa.com/>

Developing a range of new peptides products based on a detailed knowledge of marine mussels adhesion protein and a novel production that enables their exploitation. Applications include in medicine, personal care product ingredients and nutraceuticals

**Fixed Phage Ltd**[www.fixed-phage.com](http://www.fixed-phage.com)

To design, development and commercialise applications which use stabilised phage to solve bacterial challenges

**CXO/Consultant****A4Pbio**[www.a4pbio.com](http://www.a4pbio.com)

Delivers expertise in the selection, use, interpretation and bioanalysis of clinical biomarkers and pharmacokinetics across multiple therapeutic areas by engagement and management of CRO suppliers for pre-clinical and clinical studies

**Aigenpulse**[www.aigenpulse.com](http://www.aigenpulse.com)

A data management and analytics platform for scientific data generated within the field of life sciences

**Alan Boyd Consultants**[www.boydconsultants.com](http://www.boydconsultants.com)

Provide specialist consulting services for pharma and biotech companies to support their research activities and drug development

**Alderley Analytical**[www.alderleyanalytical.com](http://www.alderleyanalytical.com)

Offer specialist bioanalytical services to support drug development programmes, from discovery through to late stage clinical development, focusing on small or large molecules, peptides and biomarkers

**Antibody Analytics**[www.antibodyanalytics.com](http://www.antibodyanalytics.com)

Provide innovative solutions for the effector function characterisation of therapeutic antibodies with a specific focus on biosimilars

**Apconix**[www.apconix.com](http://www.apconix.com)

An integrated toxicology and ion channel company at the forefront of nonclinical toxicology and safety science related to ion channels in particular

**Apex Healthcare Consulting**[www.apex-consulting.co.uk](http://www.apex-consulting.co.uk)

An analytical healthcare consultancy which provides strategic business evaluations and analysis the healthcare sector in Europe and the US

**Apex Molecular**[www.apexmolecular.com](http://www.apexmolecular.com)

A synthetic chemistry company providing specialist services for the pharmaceutical, biotechnology and applied chemical sectors

**Aptus Clinical**[www.aptusclinical.com](http://www.aptusclinical.com)

Provide a range of services including full clinical study design, oversight and delivery and individual consultancy projects

**Aquila BioMedical**[www.aquila-bm.com](http://www.aquila-bm.com)

Aquila BioMedical is a preclinical contract research organisation, offering clients world-leading research expertise in immunology, immunology and multiplex histology

**Arcinova**[www.arcinova.uk](http://www.arcinova.uk)

A CDMO that provides a comprehensive range of services including process, research, development, scale-up and small scale manufacturing

**Arctoris**[www.arctoris.com](http://www.arctoris.com)

Provides a range of automated/roboticised services to support drug discovery and development particularly within oncology

**Athena Market Access Solutions**[www.athenamarketaccesssolutions.co.uk](http://www.athenamarketaccesssolutions.co.uk)

Specialise in providing pricing and reimbursement related solutions to organisations in the life sciences industry

**Aurelia Bioscience**[www.aureliabio.com](http://www.aureliabio.com)

Provide services in biological assay development, biological screening and laboratory equipment consultancy to SMEs, universities, medical charities, pharmaceutical companies and screening equipment manufacturers

**BioAscent Discovery**[www.bioascent.com](http://www.bioascent.com)

Has extensive capabilities encompassing medicinal chemistry, computational chemistry, in vitro biosciences, DMPK, compound management

**BioDivide**[www.bioidivide.com](http://www.bioidivide.com)

Aim to transform the regenerative medicine field by addressing challenges in the complete workflow from stem cell harvest, manufacture, cryostorage to clinical administration

**Biomedha**[www.biomedha.com](http://www.biomedha.com)

A CRO offering a range of pre-clinical drug development services to clients in biotech, pharma and virtual companies as well as spin-outs and academic institutions

**BioPharma Stability Testing (BSTL)**[www.biopharmastabilitytestinglaboratory.co.uk](http://www.biopharmastabilitytestinglaboratory.co.uk)

Perform analytical and biological testing services and provides access to high throughput analytical and bio-analytical testing equipment

**BioPharmaLogic**[www.biopharmalogic.com](http://www.biopharmalogic.com)

Offer services to facilitate all aspects of nonclinical drug development

**Biorelate**[www.biorelate.com](http://www.biorelate.com)

Provide biomedical research services based on their Galactic AI platform that unifies data processing, querying, deep learning and investigation

**C4X Discovery**[www.c4xdiscovery.com](http://www.c4xdiscovery.com)

Exploits cutting edge technologies to design and create small-molecule candidates in a range of therapeutic areas

**CatSci**[www.catsci.com](http://www.catsci.com)

A process research and development CRO working in the drug discovery and development area

**Celentyx**[www.celentyx.com](http://www.celentyx.com)

A CRO offering bespoke assay services in human immunology, including immuno-oncology, autoimmunity and inflammation, fibrosis and neuroinflammation

**Cello Health Consulting**[www.cellohealthconsulting.com](http://www.cellohealthconsulting.com)

Focuses on the Healthcare industry (RX / OTC & Animal Health) helping companies unlock the potential of organisations, people, assets and brands

**Cellomatics Biosciences Ltd**[www.cellomaticsbio.com](http://www.cellomaticsbio.com)

Provides expert preclinical in vitro services within oncology/immuno-oncology, immunology/inflammation and respiratory therapeutic areas

**CEM Analytical Services (CEMAS)**[www.cemas.co.uk](http://www.cemas.co.uk)

A contract analytical company specialised in generating registration data on behalf of the pharmaceutical, agrochemical and biocides industries

**Centre for Process Innovation (CPI)**[www.uk-cpi.com](http://www.uk-cpi.com)

Helps companies to develop, prove, prototype and commercialise next generation products and processes

**Charnwood Molecular**[www.charnwood-molecular.com](http://www.charnwood-molecular.com)

Provide medicinal and synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries

**Cobra Biologics**[www.cobrabio.com](http://www.cobrabio.com)

A CDMO providing biologics and pharmaceuticals for clinical and commercial supply

**CRA International**<http://www.crai.co.uk/industry/life-sciences>

A global consultancy serving diverse sectors including the life sciences

**Cytera CellWorks**[www.cytera.bio](http://www.cytera.bio)

Developing technology for automation of cell culture

**Data Magik**[www.datamagik.co.uk](http://www.datamagik.co.uk)

Offer a full clinical trial design and management service, including a complete range of statistical and data management support services

**Diamond Pharma Services**[www.diamondpharmaservices.com](http://www.diamondpharmaservices.com)

Diamond Pharma Services is a technical services and consulting group, providing expert support and advice to pharmaceutical and biotechnology companies with expertise in the cell and gene therapy space. Their three core areas are regulatory affairs, pharmacovigilance and compliance

**Diligent Business Consulting**[www.diligentglobal.com](http://www.diligentglobal.com)

Assist clients with various industry related projects, including outward and inward licensing, and supporting early/mid-stage companies wishing to become investor ready

**Domainex**[www.domainex.co.uk](http://www.domainex.co.uk)

Domainex offers a range of integrated approaches to medicinal chemistry, biochemistry and computational chemistry to assist rapid development of new therapeutics

**ERA Consulting UK**[www.eraconsulting.com](http://www.eraconsulting.com)

A regulatory affairs and product development consulting groups serving the biopharmaceutical industry. Their services covers quality, nonclinical and clinical aspects, both from the regulatory and development strategy perspective

**EUDRAC**[www.eudrac.com](http://www.eudrac.com)

A specialised regulatory affairs consultancy company providing support to drive products through development, registration, market launch and post-approval activities across all EU countries

**Evotec**[www.evotec.com](http://www.evotec.com)

Evotec is a well established CRO in the drug discovery and development space with European and US presence

**Excellerate Bioscience**[www.excelleratebio.com](http://www.excelleratebio.com)

Provide molecular pharmacology services to drug discovery companies, specialising in kinetic assay design and ligand characterisation

**Fidax Limited**

Provide international technology and life sciences senior executive experience, with extensive PLC board level and Public Sector Service. In depth background in licensing, corporate financing, IPO's, M&A and managing strategic change with blue chip companies worldwide

**Food and Drug Analytical Services (FDAS)**[www.fdas.org](http://www.fdas.org)

A contract testing laboratory, providing independent, GMP analytical services. The company's MHRA-accredited laboratories offer a full range of analytical methodologies, ICH stability storage, development and validation expertise

**GENEWIZ Europe**[www.genewiz.com](http://www.genewiz.com)

Specialises in DNA-based services, including DNA sequencing, gene synthesis, molecular biology, genomic, and GxP/CLIA regulatory-compliant services

**Gentronix**[www.gentronix.co.uk](http://www.gentronix.co.uk)

A biotechnology service company offering early screening, mechanistic follow-up and regulatory genotoxicity assays for a range of industries including pharmaceuticals, chemicals, agrochemicals, personal care, consumer products, flavours, fragrances and taste enhancers

**Gifford Bioscience**[www.giffordbioscience.com](http://www.giffordbioscience.com)

A preclinical CRO providing receptor occupancy studies, radioligand binding assays and autoradiography

**HC Pharma Consultancy**[www.helencohen4.wixsite.com/hcpharma](http://www.helencohen4.wixsite.com/hcpharma)

Provides personal guidance and support to pharma and biotech for all partnering activities for pharma products; developing partnering strategies, leading out-license campaigns, in-license searches, due diligence, negotiation of contracts or management of alliances

**Hematogenix Laboratory Services**[www.pharma.hematogenix.com](http://www.pharma.hematogenix.com)

A GCP compliant and CAP and CLIA certified laboratory offering clinical trial biomarker services including flow cytometry, FISH, IHC, mRNA ISH, PCR, sequencing, and many more

**High Force Research**<https://highforceresearch.com/>

Provide bespoke chemical design and synthesis services

**HistologiX**[www.histologiX.co.uk](http://www.histologiX.co.uk)

A privately owned GLP/GCP accredited contract research organisation that provides pathology services for the pharmaceutical and biotechnology industry. They provide human tissue based solutions in support of regulatory preclinical programmes, clinical trials in addition to biomarker projects

**Horizon Discovery**[www.horizondiscovery.com](http://www.horizondiscovery.com)

Provide a range of services to support drug discovery including functional genomics and high throughput screening using sophisticated CRISPR generated lines, animal models and gene editing (using CRISPR technology)

**Imagen Therapeutics**[www.imagentherapeutics.com](http://www.imagentherapeutics.com)

Provide a complete high content screening service for large pharma and small biotech. The company offers a wide range of image-based assays including neuronal, angiogenic, cellular signalling, and other complex morphological assays.

**InClinica**[www.inclinica.com](http://www.inclinica.com)

A global clinical CRO that specialises in leading companies through clinical trials and applying their in-depth experience and expertise in clinical research and drug development

**Invicro**[www.invicro.com](http://www.invicro.com)

An imaging science company that provides advanced data analysis services and software in the growing field of pre-clinical imaging research

**Invivo Clinical T/A Bionomics**[www.invivoclinical.co.uk](http://www.invivoclinical.co.uk)

A healthcare company that offers the latest advancements in bioscience, diagnostics and therapeutics to healthcare practitioners and their patients

**Jon Rees Associates**[www.jonreesassociates.com](http://www.jonreesassociates.com)

A specialist consultancy with a focus on the interface between investment and innovation.

**Kaleidoscope Consultants**[www.kaleidoscopeconsultants.com](http://www.kaleidoscopeconsultants.com)

Data privacy consultants

**Kelyon**[www.kelyon.com](http://www.kelyon.com)

An ICT company which specialises in the design and development of software medical devices, web and mobile applications based on open source technologies, for big pharmaceutical companies, medical-scientific associations, and healthcare facilities

**Kinomica**[www.kinomica.com](http://www.kinomica.com)

Kinomica is a proteomic-data science and diagnostics company specialising in cell signalling. They offer a suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage

**Leaf Expression Systems**[www.leafexpressionsystems.co.uk](http://www.leafexpressionsystems.co.uk)

A CDMO specialising in plant-based expression systems and the production of custom proteins

**Lonza Biologics**[www.lonza.com](http://www.lonza.com)

Operates as a contract manufacturer of monoclonal antibodies and recombinant protein and engages in protein engineering, viral testing, toxicology studies, and clinical trials.

**Ludger**[www.ludger.com](http://www.ludger.com)

Specialises in analytical technology for medical applications of glycobiology and manufactures a comprehensive range of kits and reagents for ICH-compliant glycoprofiling of biopharmaceuticals throughout the drug development cycle

**Manentia**[www.manentia.co.uk](http://www.manentia.co.uk)

A full service CRO that delivers clinical development service for whole programmes or individual projects

**Menarini Biotech UK**[www.menarini-biotech.com](http://www.menarini-biotech.com)

A CDMO that provides expertise in production of biosimilars, innovative monoclonal antibodies and other recombinant proteins

**MicrobesNG**<https://microbesng.com>

Provide a range of Illumina based genome sequencing services

**Mologic**[www.mologic.co.uk](http://www.mologic.co.uk)

A CRO working in the diagnostics space. It offers services in the research, development and manufacture of lateral flow based in vitro diagnostic devices

**myClin Europe**[www.myclin.com](http://www.myclin.com)

Offers a clinical oversight platform that allows users to share documents efficiently, improve engagement and stay audit-ready at all times

**NDA Regulatory Science**<https://www.ndareg.com/>

A leading regulatory and drug development consultancy with a dedicated team of over 150 consultants supported by an expert network and a specialist Advisory Board

**NDY Consulting**[www.ndy.com](http://www.ndy.com)

Consulting engineers

**Oxford Expression Technologies**[www.oetltd.com](http://www.oetltd.com)

CRO with expertise in baculovirus protein expression

**Patheon, part of ThermoFisher**[www.patheon.com](http://www.patheon.com)

Patheon, now part of ThermoFisher, provides drug development and manufacturing services to the ThermoFisher group and works in close association with Fisher Clinical Services

**Peak Proteins**[www.peakproteins.com](http://www.peakproteins.com)

Provides protein supply and structure based drug discovery services to clients

**Pharmaron**[www.pharmaron.com](http://www.pharmaron.com)

An R&D service provider supporting a wide range of services, from early discovery to clinical development

**Pharmidex Pharmaceutical Services**[www.pharmidex.com](http://www.pharmidex.com)

Provide translational solutions using its expertise in CNS/oncology/ respiratory, DMPK, drug discovery and ADMET/pharmacokinetics

**Phastar**[www.phastar.com](http://www.phastar.com)

A global CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships

**Phosphonics**[www.phosphonics.com](http://www.phosphonics.com)

Developing custom and off-the-shelf technologies for removal or recovery of traces of a wide range of metals in product, process or waste stream. Applications in pharmaceutical preparation and chemical production

**Physiomics**[www.physiomics-plc.com](http://www.physiomics-plc.com)

Provide outsourced systems and computational biology services to pharmaceutical companies including Virtual Tumour, Virtual Tumour Preclinical and services to predict cardiac toxicity

**Precision for Medicine, Oncology and Rare Disease**[www.precisionmedicinegrp.com/pfmord/](http://www.precisionmedicinegrp.com/pfmord/)

An oncology specialty CRO that provides clinical research services and application of metrics-driven project management to optimise oncology drug development

**Prisma Limited**[www.prisma.com](http://www.prisma.com)

Prisma is a biotech software development company with experience in research informatics, biology, software and mathematics and offering consulting services to solve one-off complex problems up to crafting efficient, everyday, elegant solutions

**Q3 Analytical**[www.bioanalysisforresearch.com](http://www.bioanalysisforresearch.com)

Provide non-regulated bioanalytical support for small pharmaceutical companies carrying out drug discovery and research and also analyse in-vitro samples generated by the client's own in-house biological assays

**Quotient Sciences**<https://www.quotientciences.com/>

Provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry

**Reach Separations**[www.reachseparations.com/](http://www.reachseparations.com/)

Specialise in chromatography techniques for the analysis and purification of small molecules, offering screening, method development and purification for chiral and achiral molecules

**RenaSci**[www.renasci.co.uk](http://www.renasci.co.uk)

Provide highly specialised consultancy and preclinical experimental services to the global pharmaceutical industry in the areas of abuse and dependence, CNS, obesity, diabetes, NASH and kidney disease

**Rockpool Biosciences**[www.rockpoolbio.com](http://www.rockpoolbio.com)

Provides genomics and AI consultancy services

**RSSL**[www.rssl.com](http://www.rssl.com)

Provide analytical, investigational, consultancy and training services to clients in the global biopharmaceutical, pharmaceutical and healthcare industries

**SAL Scientific Limited**[www.salscientific.com](http://www.salscientific.com)

Cell biology specialists providing contract research services and animal-component-free cell culture media supplements to a global client base

**S-cubed**[www.s-cubed.co.uk](http://www.s-cubed.co.uk)

S-cubed provides consultancy and support services to pharmaceutical and healthcare clients across a comprehensive range of regulatory, quality assurance and biometrics activities

**Seda Pharmaceutical Development Services**[www.sedapds.com](http://www.sedapds.com)

Seda Pharmaceutical Development Services provide pharmaceutical development and clinical pharmacology services and consultancy to the pharma and biotechnology industry

**Shanghai Medicilon Inc**[www.medicilon.com.cn](http://www.medicilon.com.cn)

Provide a wide range of contract services for development of new drugs

**SPG Innovation**[www.SPGinnovation.co.uk](http://www.SPGinnovation.co.uk)

Commercialisation of Intellectual Property in food, life sciences and agritech providing wide range of services in this area

**Syneos Health**[www.syneoshealth.com](http://www.syneoshealth.com)

Use their Biopharmaceutical Acceleration Model to assist clients with clinical and commercial development

**Tetrad Discovery**[www.t4bio.com](http://www.t4bio.com)

A CRO providing bespoke bio-analysis solutions tailored and integrated to the sponsors requirements, using state-of-the-art technologies

**TranScrip Partners**[www.transcrip-partners.com](http://www.transcrip-partners.com)

Provide support for the development and lifecycle management of biopharmaceutical products in the field of oncology, respiratory, internal medicine, and CNS

**Upperton Pharma Solutions**[www.upperton.com](http://www.upperton.com)

A research and development company that specialises in the formulation and spray drying of pharmaceutical and biotechnology products

**Vivonics Preclinical**[www.vivonics-preclinical.com](http://www.vivonics-preclinical.com)

A CRO providing preclinical services and consultancy to the biotech and pharmaceutical industry

**Williamson Biotech Solutions**[www.williamsonbiotechsolutions.com](http://www.williamsonbiotechsolutions.com)

Offer facilitating services to biotech, medtech, pharma and academic institutions delivering communication, marketing and business development services

**Wuxi AppTec**[www.wuxiapptec.com](http://www.wuxiapptec.com)

A pharmaceutical, biotechnology, and medical device R&D service provider with operations in China and the United States

**XenoGesis**[www.xenogesis.com](http://www.xenogesis.com)

Specialises in preclinical drug metabolism and pharmacokinetics, quantitative bioanalysis, and data interpretation services

**GenScript Biotech BV**[www.genscript.com/](http://www.genscript.com/)

Provide a range of services and products in the areas of synthesis of genes, proteins, antibodies and molecular biology

**Molecule 2 Medicine**<https://molecule2medicine.com/>

Professional consulting services for small biotech companies to help them develop robust drug discovery and development programmes

**Academic Institution****Oxford Brookes University**[www.brookes.ac.uk](http://www.brookes.ac.uk)

One of the UK's 'modern' universities and provides teaching and innovation as well as strong links with business and industry

**Queen Mary Innovation**[www.qminnovation.co.uk](http://www.qminnovation.co.uk)

Queen Mary Innovation Ltd (QMI) is Queen Mary University of London's (QMUL) wholly-owned technology transfer company and responsible for the commercialisation and management of the University's intellectual property and portfolio of spinout companies

**Queen's University Belfast Research and Enterprise Directorate**[www.qub.ac.uk/Research/Research-contacts/](http://www.qub.ac.uk/Research/Research-contacts/)

Help to deliver research and enterprise activities through the development of research strategy and policy.

**Royal Veterinary College Business**[www.rvc.ac.uk/business](http://www.rvc.ac.uk/business)

The Royal Veterinary College's interface with business and industry

**University of Birmingham Enterprise**[www.birmingham.ac.uk/enterprise](http://www.birmingham.ac.uk/enterprise)

Supports academics who want to innovate, take their ideas to market, work with businesses and social enterprises, or enrich their professional lives by doing academic consultancy projects.

**Warwick Ventures**[www.warwickventures.com](http://www.warwickventures.com)

Is the technology transfer business unit of the University of Warwick and supports them throughout the process of generating impact and a commercial return from their research.

**Rosalind Franklin Institute**[www.rfi.ac.uk](http://www.rfi.ac.uk)

A new Research institute dedicated to transforming life science through interdisciplinary research and technology development

**R&D Support****2BScientific Ltd**<https://www.2bscientific.com/>

Europe's fastest growing distributor of life science reagents

**4T2 Sensors**[www.4t2sensors.com](http://www.4t2sensors.com)

Developing an in-line flow sensor system that can detect concentrations, contaminations and mixtures of fluids

**Absolute Antibody**[www.absoluteantibody.com](http://www.absoluteantibody.com)

Develop engineered antibodies for the research and diagnostics markets

**ACE Cells Lab**[www.ace-cells.co.uk](http://www.ace-cells.co.uk)

A biomolecular lab specialised in providing bioactive peptides and proteins from a range of different cells and tissues

**Air Liquide UK**[www.uk.airliquide.com](http://www.uk.airliquide.com)

A producer and supplier of industrial and medical gases and related services

**Air Products**[www.airproducts.co.uk](http://www.airproducts.co.uk)

Provides atmospheric and process gases and related equipment to manufacturing markets and is also a supplier of liquefied natural gas process technology and equipment

**AMS Biotechnology (Europe)**[www.amsbio.com](http://www.amsbio.com)

Specialise in genomics, proteomics, cell culture and stem cell sciences, providing products and custom services for life sciences research

**anvajo GmbH**[www.anvajo.com](http://www.anvajo.com)

A technology company that develops, manufactures and sells innovative solutions for the analysis of liquid samples

**ATG Scientific**[www.atgscientific.co.uk](http://www.atgscientific.co.uk)

A supplier of laboratory products and equipment solutions to support life sciences research

**Aver Decommissioning & Environmental**[www.averdecom.com](http://www.averdecom.com)

A specialist decommissioning and environmental consultancy working across a wide range of industrial sectors in the UK and overseas

**Avidity IP**<https://avidity-ip.com/>

Commercially focused European & UK patent attorneys specialising in Life Sciences and Medical Technologies with a growing Engineering initiative.

**Avitus Group Companies**[www.avitusgroup.com](http://www.avitusgroup.com)

Provide a range of services for growing businesses including accounting, payroll, HR, insurance, recruiting amongst many others

**Biogelx**[www.biogelx.com](http://www.biogelx.com)

A biomaterials company which designs and supplies peptide hydrogels tuned to the requirements of cells to be used for 3D cell culture and bioprinting

**Bio-Rad AbD Serotec**[www.bio-rad-antibodies.com](http://www.bio-rad-antibodies.com)

Provide a wide range of reagents, particularly antibodies, for life sciences research

**BMG Labtech**[www.bmglabtech.com](http://www.bmglabtech.com)

A leading manufacturer of high-quality, innovative microplate reader instrumentation

**Bruntwood Scitech**<https://bruntwood.co.uk/about-bruntwood/scitech/>

The UK's leading property provider dedicated to driving the growth of the science and technology sector

**Enplas**<https://www.enplasilifetech.com/>

A global corporation with diverse interests. Enplas Life Tech is the leading single-source manufacturer of high-quality custom plastics parts for global OEMs in the medical, biotech, pharmaceutical, and life science industries

**Fisher Scientific UK**[www.fishersci.co.uk](http://www.fishersci.co.uk)

Manufactures and supplies laboratory chemicals and laboratory equipment.

**Merck**<https://www.merckgroup.com/en>

Merck is a long-established major pharmaceutical giant with diverse interests spanning healthcare/medicine development, diagnostics, support of biotech, pharma and biopharma manufacturing and running through to cosmetics

**New England Biolabs (UK) Ltd**<https://www.neb.uk.com/>

Provide a wide range of lab reagents and kits to support R&D

**NgaChi**

A biotech startup hosted in The Biohub Birmingham and is currently working on the development of a new laboratory consumable

**Nikalyte Ltd**[www.nikalyte.com](http://www.nikalyte.com)

Nikalyte Ltd is a leading supplier of various nanoparticles coatings for R&D and commercialization in a wide variety of application areas including cell binding, cell separation, drug delivery, catalysis, metamaterials, nano-photonics, electrochemistry, and batteries

**Nonacus**[www.nonacus.com](http://www.nonacus.com)

Focus on delivering technologies to the genomic healthcare sector through the use of cell free circulating DNA as a non-invasive diagnostic tool

**Northern Balance**[www.northernbalance.co.uk](http://www.northernbalance.co.uk)

One of the UK's leading independent distributors of weighing equipment, supplying, servicing and calibrating some of the worlds most trusted brands

**PeproTech EC**[www.peprotech.co.uk](http://www.peprotech.co.uk)

Focus on the development and manufacturing of cytokine products for the life-science and cell therapy markets.

**RS Components**[www.uk.rs-online.com/web/](http://www.uk.rs-online.com/web/)

Provides a vast range products, in particular electronic, electrical and industrial components

**Sigma Aldrich/Merck**[www.sigmaaldrich.com](http://www.sigmaaldrich.com)

A leading global life science and high technology company with their products being used worldwide to enable science that improves the quality of life

**Thermo Fisher**[www.corporate.thermofisher.com](http://www.corporate.thermofisher.com)

Provide a vast range of consumables, reagents and equipment to the life sciences industry

**Tissue Solutions**[www.tissue-solutions.com](http://www.tissue-solutions.com)

Is an ISO 9001:2015 accredited provider of high quality human biomaterials for pre-clinical and discovery biomarker research

**Tracer Measurement Systems**[www.birminghamresearchpark.co.uk/tenants/tracer-measurement-systems-ltd](http://www.birminghamresearchpark.co.uk/tenants/tracer-measurement-systems-ltd)

Provide applications R&D, sales & marketing of mobile chemical ionisation mass spectrometers

## Charity Organisation

**Kirkhouse Trust**[www.kirkhousetrust.org](http://www.kirkhousetrust.org)

Is a small charity which aspires to improve the food security and livelihood of the rural poor in sub-Saharan Africa and India

**Oxford Trust**[www.theoxfordtrust.co.uk](http://www.theoxfordtrust.co.uk)

Encourage and facilitates the study, application and communication of science, technology, engineering and mathematics

## Investors and Advisors

**Akesios Associates**[www.akesiosassociates.com](http://www.akesiosassociates.com)

Provides financial strategy, representation and commercial development advice to life science companies.

**Cambridge Innovation Capital**[www.cambridgeinnovationcapital.com](http://www.cambridgeinnovationcapital.com)

An investment fund that invests in high-growth technology companies in diverse sectors

**Downing**[www.downing.co.uk](http://www.downing.co.uk)

Offer management of investment products for investors such as venture capital trusts, enterprise investment schemes, inheritance tax mitigation funds, business premises renovation allowance schemes, and an open ended investment company

**G. Knight Consulting**

Provides an independent life science strategy and mergers/acquisitions consulting services for private equity and corporate companies

**Longwall Venture Partners**[www.longwallventures.com](http://www.longwallventures.com)

An Oxford based, venture capital fund management company that specialises in managing early stage investments in science, engineering and technology start-ups

**Midven**[www.midven.co.uk](http://www.midven.co.uk)

Is a private equity and venture capital firm specialising in start-up, early stage, growth, management buy-outs, and management buy-ins investments in small and medium sized enterprises

**Norgine Ventures Management**[www.norgineventures.com](http://www.norgineventures.com)

Provide debt and debt-like financing to companies in the fields of healthcare and life sciences, in Europe and the US

**Results Healthcare**[www.resultshealthcare.com](http://www.resultshealthcare.com)

Provide corporate finance expertise and strategic business advice to the healthcare sector

**Silicon Valley Bank**[www.svb.com](http://www.svb.com)

Provide a full range of financial services to companies of all sizes in innovation centers around the world

**SR One**[www.srone.com](http://www.srone.com)

Specialise in investing in seed, start up, early and mid venture; and emerging growth companies

**SV Health Managers**[www.svlsa.com](http://www.svlsa.com)

Is a healthcare and life sciences venture capital and growth equity firm managing over \$2 billion in capital in seven private healthcare funds in the US and Europe

## Associated Industry

**AggioSergeant**[www.aggiosergeant.com](http://www.aggiosergeant.com)

Specialise in life sciences executive search and company culture change.

**Alderley Park**[www.alderleypark.co.uk](http://www.alderleypark.co.uk)

Offer bioscience facilities for R&D focussed life science companies at every stage of their life-cycle, from start-up to global corporate.

**BDO**[www.bdo.co.uk](http://www.bdo.co.uk)

Global accounting and financial consultancy

**BioCity Group**[www.biocity.co.uk](http://www.biocity.co.uk)

A bioscience incubator, providing the conditions that sustain more than 80 fast-growing businesses. incubator, providing the conditions that sustain more than 80 fast-growing businesses. It has centres in Nottingham, Alderley and Glasgow

**BioHub Birmingham**[www.thebiohub.co.uk](http://www.thebiohub.co.uk)

A fully serviced biomedical research laboratory providing entrepreneurs and innovative start-ups with access to affordable laboratory facilities and equipment

**Biotech Personnel**[www.biopers.co.uk](http://www.biopers.co.uk)

An HR consultancy business which specialises in start-up assistance, recruitment, reward management, policy and procedures and culture change programmes

**Biotechgate**[www.biotechgate.com](http://www.biotechgate.com)

Provide a business development database for the life sciences industry

**British Columbia Trade and Investment**<https://www.britishcolumbia.ca/global/trade-and-investment-representatives/>

Trade and Invest B.C. works with international enterprises to help them build strong links to the resources, skills and businesses that make British Columbia an attractive place to work and invest

**Bulb Laboratories**[www.bulblaboratories.com](http://www.bulblaboratories.com)

Build and furnish commercial interiors from corporate offices to high-tech laboratories

**Citigate Dewe Rogerson**[www.citigatedewerogerson.com](http://www.citigatedewerogerson.com)

An international public relations firm offering the full range of communications services to companies, both domestically and internationally

**Cleveland Scott York**[www.csy-ip.com/](http://www.csy-ip.com/)

A global IP firm

**Coulter Partners**[www.coulterpartners.com](http://www.coulterpartners.com)

An executive search and management consulting firm assisting healthcare, pharmaceutical, biotechnology, and financial services sectors

**Dehns**[www.dehns.com](http://www.dehns.com)

A UK firm of Patent and Trade Mark Attorneys advising on all aspects of patenting innovative technology, registering words, logos and other marks and registering original designs

**Destination Cloud**[www.destinationcloud.co.uk](http://www.destinationcloud.co.uk)

A next generation Cloud Managed Service Provider, active in the UK and Europe, offering specialist cloud business transformation solutions to businesses

**DiagnOx**[www.diagnox.co.uk](http://www.diagnox.co.uk)

An incubator facility based at the Cherwell Innovation Centre in North Oxfordshire. Owned by Oxford Innovation

**Discovery Park Limited**[www.discovery-park.co.uk](http://www.discovery-park.co.uk)

A science park based on the old Pfizer site at Sandwich and home to a growing number of life sciences companies

**EFR Travel**[www.efrtravel.co.uk](http://www.efrtravel.co.uk)

Specialise in corporate travel as well as high end leisure and golfing holidays, private jet travel and a concierge division providing tickets for sold out events. EFR is a provider to the OBN Purchasing Consortium

**Elcom Systems**[www.elcom.com](http://www.elcom.com)

The world's first cloud-based procurement technology company. They provide solutions for e-invoicing, e-procurement, and e-funding to optimise the clients' Supply Chain processes and are the providers of the OBN Purchasing Platform

**Elsevier**[www.elsevier.com](http://www.elsevier.com)

Provide information and analytics that help institutions and professionals progress science, advance healthcare and improve performance

**Ethical Medicines Industry Group (EMIG)**[www.emig.org.uk](http://www.emig.org.uk)

A multi-stakeholder network and trade industry association that represents the interests of the full span of life sciences companies in the UK

**Fieldfisher**[www.fieldfisher.com](http://www.fieldfisher.com)

A multinational law firm which has practices in sectors including Real Estate, Energy, Financial Services, Government & Public Services, Hotels & Leisure, Life Sciences, Media, Telecoms and Technology.

**First Create the Media**[www.firstcreatethemedia.com](http://www.firstcreatethemedia.com)

Is a communications consultancy for people that work in science. The company provides consultancy, copywriting, podcast and video production, science communication training and one-to-one coaching

**Fourtold Ltd**[www.fourtold.eu](http://www.fourtold.eu)

Experts in corporate, reputation and political communications

**FTI Consulting**[www.fticonsulting-emea.com](http://www.fticonsulting-emea.com)

Provide legal tax advice to UK based life sciences companies

**Gallagher**[www.ajginternational.com](http://www.ajginternational.com)

Is active in insurance brokerage and risk management providing insurance solutions for a wide range of different businesses including the life sciences

**george james**[www.georgejamesltd.co.uk](http://www.georgejamesltd.co.uk)

Provide European recruitment and global strategic consulting and training services covering the biotechnology, pharmaceuticals, medical devices, diagnostics, instrumentation, scientific software, fine chemicals and chemical technology markets

**Greaves Brewster**[www.greavesbrewster.co.uk](http://www.greavesbrewster.co.uk)

Handles the preparation, filing, prosecution and maintenance of patent, trade mark and design applications

**Harwell Campus**<https://www.harwellcampus.com/>

Is a science, innovation, technology and business campus and hosts an array of over £1 billion of research infrastructure

**Hayes Parson Insurance Brokers**[www.hayesparsons.co.uk](http://www.hayesparsons.co.uk)

Independent insurance brokers for the South West of England

**Instinctif Partners**[www.instinctif.com/uk](http://www.instinctif.com/uk)

Instinctif Partners provides communications consultancy services for science based sectors including corporate, healthcare, and marketing communications, as well as financial communications

**Interea International**[www.interea.co.uk](http://www.interea.co.uk)

A provider of middle to senior level interim management to UK and international life science and related companies (biotech, pharma, medical device, diagnostic, regenerative medicine etc.)

**IP Asset Partnership, The**[www.ipasset.com/](http://www.ipasset.com/)

A specialist practice of patent attorneys that provide specific advice or assistance on all IP related matters

**JA Kemp**[www.jakemp.com](http://www.jakemp.com)

Patent and trade mark attorneys

**James Cowper Kreston**[www.jamescowper.co.uk](http://www.jamescowper.co.uk)

A firm of accountants and business advisors based in Henley, London, Newbury, Oxford, Reading and Southampton

**KISS Communications**[www.kisscom.co.uk](http://www.kisscom.co.uk)

Is a strategy-led agency that integrates advertising, branding, digital and public relations services, and works with companies in industries such as healthcare, science, technology, research and development

**Mary Ann Liebert Publishers**<https://www.liebertpub.com/>

A leading independent publisher known worldwide for its peer-reviewed journals, books, and trade publications

**MediCity Nottingham**[www.biocity.co.uk/locations/medicity-nottingham/](http://www.biocity.co.uk/locations/medicity-nottingham/)

Provide a stimulating and supportive business development environment for innovators in consumer healthcare, medical technology, diagnostics and beauty products

**MEPC Milton Park**[www.miltonpark.co.uk](http://www.miltonpark.co.uk)

A premium business and science park located near Abingdon. Part of the MEPC group

**Middle East Medical Portal**[www.middleeastmedicalportal.com](http://www.middleeastmedicalportal.com)

The premier medical portal between the West and the Middle East

**Mills & Reeve**[www.mills-reeve.com](http://www.mills-reeve.com)

A commercial law firm offering corporate, commercial, property, litigation and private client services to a mix of regional, national and international businesses

**North**[www.north-51.com](http://www.north-51.com)

Engages in building, managing, and motivating sales teams including contract sales teams, nurse adviser teams, NHS liaison teams and specialist hospital teams

**OEG Laboratories**[www.oeglabs.co.uk](http://www.oeglabs.co.uk)

OEG Labs offers a full project-managed lab fit-out solution, from initial design through to custom manufacture and installation to customers in the UK

**Osborne Clarke**[www.osborneclarke.com](http://www.osborneclarke.com)

Provide legal services to meet clients' advisory, litigation and transactional needs in an international business environment that is reshaping to meet new digital, economic, environmental and political challenges

**Oxford Bioescalator**[www.bioescalator.ox.ac.uk](http://www.bioescalator.ox.ac.uk)

Provide flexible lab space near the centre of Oxford to early stage biomedical science companies

**Oxford Innovation Limited**[oxin-centres.co.uk](http://oxin-centres.co.uk)

The UK's leading innovation and incubation centre operator. Also providing feasibility and consultancy services and design and financial modelling

**Oxford Science Park**[www.oxfordsp.com](http://www.oxfordsp.com)

Is designed for science, technology and business occupiers, maintains links with the University of Oxford and currently contains just over 70 companies

**Oxford Seating Co**[www.oxfordseating.co.uk](http://www.oxfordseating.co.uk)

Designs and manufactures seating and related furniture for companies in many different industries

**Oxford Technology Park**[www.oxfordtechnologypark.com](http://www.oxfordtechnologypark.com)

New science and technology park in Oxford

**Penningtons Manches Cooper**[www.penningtonslaw.com](http://www.penningtonslaw.com)

Is a law firm providing legal services to ultra high net worth individuals and growing mid-market companies.

**PharmaGuide**[www.pharmaguide.co.uk](http://www.pharmaguide.co.uk)

Offer drug discovery courses to a range of clients from professionals with no scientific background, up to PhD level scientists

**Phoenix IFD**[www.linkedin.com/in/james-robson-943ab41/?originalSubdomain=uk](http://www.linkedin.com/in/james-robson-943ab41/?originalSubdomain=uk)

A life sciences and healthcare consulting business that focuses on innovative start ups in the pharmaceutical, healthcare and medtech sectors

**PIA Life Science Insurance Brokers**[www.piacommercial.com](http://www.piacommercial.com)

Provide a range of specialist insurance products for individuals and businesses, including those in the life sciences sectors

**PiR**[www.pir-intl.com](http://www.pir-intl.com)

A specialist recruitment company serving the international life sciences industry through executive search, interim management and talent management/mapping

**Principlelabs/Office Laboratories**<https://principlelabs.co.uk/>

Expert laboratory design and build

**ProcEurope**[www.proceurope.com/](http://www.proceurope.com/)

Providing the power of a purchasing consortium to the life sciences sector in Europe through providing negotiable rates and specially selected suppliers

**Release Life Sciences and Diagnostics**[www.releaselifesciences.com](http://www.releaselifesciences.com)

Help life science and diagnostics companies by providing commercial and marketing management services, interim management, training and development and career development and coaching

**Richardsons Chartered Accountants**[www.richardsons-group.co.uk](http://www.richardsons-group.co.uk)

Provide accounting, audit and taxation advice (compliance and planning) to enterprises and individuals, along with payroll and financial services

**Ridgefield Consulting**[www.ridgefieldconsulting.co.uk](http://www.ridgefieldconsulting.co.uk)

An independent firm of Chartered Accountants provides accounting, tax advice and planning to businesses and individuals

**SJB Technical Recruitment**[www.sjbtechnical.co.uk](http://www.sjbtechnical.co.uk)

Specialises in recruiting engineers and scientists to start-ups and SMEs with particular focus on medical engineering, engineering design consultancies, entrepreneurial firms and new technology

**SRG**[www.srg.co.uk](http://www.srg.co.uk)

Is UK supplier of scientific, clinical and engineering recruitment solutions to the pharmaceutical, biotechnology, medical devices, FMCG, renewable energy, chemical and food processing industries

**Starleaf**[www.starleaf.com](http://www.starleaf.com)

Video conferencing

**Sue Rees Associates**[www.suerees.co.uk](http://www.suerees.co.uk)

An accountancy executive search specialist supporting board level executives within the biotech, pharma, life sciences, start up and spin out companies

**Taylor Wessing**<https://www.taylorwessing.com/en>

A global law firm providing services across many sectors including the life sciences

**TBAT Innovation**[www.tbat.co.uk](http://www.tbat.co.uk)

An independent consultancy that provides services and advice on grant funding, R&D taxation, and project management

**Unit DX**[www.unitdx.com](http://www.unitdx.com)

A Bristol-based scientific innovation centre, catering for start-ups, SMEs and industrial team providing lab space, equipment, analytical services, expert support and facilitates cooperation between companies

**Utility Team**[www.utilityteam.co.uk](http://www.utilityteam.co.uk)

One of the UK's leading utilities and energy consultants, providing a wide range of value added utility that saves time and money

**VA Beach Bio**[www.vabeachbio.com](http://www.vabeachbio.com)

A business organisation that aims to market the Virginia Beach area as a prime location for life sciences companies moving to the US

**Venner Shipley**[www.vennershipley.co.uk](http://www.vennershipley.co.uk)

Is a firm of European patent and trade mark attorneys, representing a broad range of clients including major domestic and international corporations, SMEs, universities and individual inventors



**VirdisGroup**

[www.virdisgroup.com](http://www.virdisgroup.com)

Is an executive search firm specialising in the lifescience and healthcare sectors

**Wallder Limited**

[www.wallder.com](http://www.wallder.com)

A UK-based executive search, interim management, and resourcing company that builds boards and senior management teams in the life sciences sector

**Helixr**

[www.helixr.com](http://www.helixr.com)

Helixr is a business consulting firm offering services to life sciences companies across business restructuring, global tax technologies and ERP programs, including end-to-end project management solutions

**Elementa Consulting**

[www.elementaconsulting.com](http://www.elementaconsulting.com)

MEP building services and sustainability consultancy specialising in low energy building design

**Jackson Hogg**

[www.jacksonhogg.com](http://www.jacksonhogg.com)

Recruitment and outsourced staffing, HR consultancy, training provider

**Restore Harrow Green**

[www.harrowgreen.com](http://www.harrowgreen.com)

Laboratory relocation/storage and distribution

**Focus Oxford Risk Management**

[focusorm.co.uk](http://focusorm.co.uk)

Provide bespoke insurance solutions for commercial, business and private clients

**Government Organisation**

**AMR Centre UK**

[www.amrcentre.com](http://www.amrcentre.com)

AMR Centre is a key part of the UK's response to the global threat from antimicrobial resistance to accelerate the development of new antimicrobial drugs and diagnostics

**Embassy of Belgium**

[www.diplomatie.be](http://www.diplomatie.be)

The London embassy of the Belgian Government and is active in the area of life sciences and collaboration between the UK and Belgium

**Embassy of Switzerland, London - Office of Science, Technology and Higher Education**

[www.eda.admin.ch](http://www.eda.admin.ch)

The Office serves as an interface between the science and technology communities in Switzerland and the UK by providing information and facilitating contacts. The office works with government, universities and business to organise bilateral networking, matchmaking events and joint projects

**HR Dept**

[www.hrdept.co.uk/newbury](http://www.hrdept.co.uk/newbury)

Provide HR services to support companies with employment contracts, managing disciplinarys or other employment issues

**Innovate UK**

[www.innovateuk.org](http://www.innovateuk.org)

Work with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy and provides invaluable support to the life sciences through its grants programmes

**Medicines Discovery Catapult**

[www.md.catapult.org.uk](http://www.md.catapult.org.uk)

Is a national facility for collaborative R&D projects and developing new approaches to the discovery and proof of utility of medicines, diagnostics and biomarkers

**Netherlands Foreign Investment Agency**

[www.investinholland.com](http://www.investinholland.com)

The inward investment agency for The Netherlands

**Public Health England**

[www.gov.uk/government/organisations/public-health-england](http://www.gov.uk/government/organisations/public-health-england)

Their mission is to protect and improve the nation's health and to address inequalities through working with national and local government, the NHS, industry and the voluntary and community sector

**West Midlands Growth Company**

[www.wmgrowth.com](http://www.wmgrowth.com)

A regional investment promotion and economic development agency, unlocking potential for the West Midlands and the UK with the primary purpose is to attract investment, jobs, visitors and business to the West Midlands

**Other**

**Aliksir**

[www.aliksir.co.uk](http://www.aliksir.co.uk)

Develop sensor systems to drive improvements in water quality testing



If you're relocating your laboratory, Restore Harrow Green are the experts you can trust to handle every aspect of your project. Our advanced knowledge of laboratory operations means we are able to handle:

- Samples, and chemicals, including dangerous and hazardous goods
- All types and sizes of moves—we specialise in complicated projects
- Instruments and all types of equipment
- Cold chain materials
- IT, data and archives
- Clean Rooms
- Office, write up, and break out areas

**We provide:**

- ✔ A high Level of Service & Technical ability
- ✔ A dedicated Lab Project Manager
- ✔ An in-house DGSA

**We guarantee: Your peace of mind!**



We have branches in every major UK city and can undertake any size lab move. We also store and distribute all types of equipment.

In addition, our new, lab dedicated facility in Cambridge, is ready and waiting to support the area's research parks and wider scientific community.



RHG Laboratory Services



@HarrowGreen



[www.harrowgreen.com](http://www.harrowgreen.com)



[labprojects@restore-harrowgreen.com](mailto:labprojects@restore-harrowgreen.com)



0345 603 8774



Check out our website at [www.obn.org.uk](http://www.obn.org.uk) for all the latest OBN news and events



# NEXT ISSUE

CONNECT issue 5 will be available  
Autumn 2021

Please contact Rebecca Wilkes,  
Communications and  
Marketing Coordinator,  
[rebecca.wilkes@obn.org.uk](mailto:rebecca.wilkes@obn.org.uk),  
if you would like :

- to contribute to the next CONNECT
- place an advert
- provide feedback

We look forward to  
hearing from you!



## Contact details:

### Main Office

OBN (UK) Ltd  
5F Park Square, Milton Park, Abingdon,  
Oxfordshire, OX14 4RR, UK

Tel: +44 (0) 1235 420 870

[www.obn.org.uk](http://www.obn.org.uk)



@OBN\_UK



OBN (UK) Ltd